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Secondary injury elicits a complex series of pathophysiological events after the primary 
spinal cord trauma and even after its implantation treatment for neural functional 
recovery. These secondary injuries include an up-regulation of glial cells associated 
reactive oxygen species, nitrogen species, and reactive astrogliosis, and they can result in 
various levels of cellular and tissue damage.  The inhibition of them has been proved to 
lead to functional recovery of the spinal cord. In this study, we concentrated on 
developing polymers and nano-techniques based drug delivery strategies to eliminate 
these secondary injuries.  
To maintain and improve the performance of the implants during treatment,  we exploited 
the polypyrrole as a suitable material to carry and locally release the drug at the injured 
spinal cord based on its conductive characteristics.  We focused on the geometric 
modulation of implants materials on a nano-size scale and developed a polypyrrole 
nanowire platform that can served as a high capacity drug reservoir and can release drugs  
in a relatively longer time. Most importantly, we introduced the electromagnetic 
responsive feature of polypyrrole for drug delivery. This valuable technique can help us 
xiii 
 
to achieve a non-invasive and remotely controlled drug release in deep tissues and avoid 
the physical contacts commonly required during traditional electrical stimulation. We 
used dexamethasone as a drug cargo, since this drug is commonly used for anti-
inflammation treatment and has been successfully delivered from polypyrrole using 
conventional electrical stimulation methods in earlier studies. According to the results, 
we showed successful and long lasting polypyrrole mediated drug release under 
electromagnetic stimulation and the released drugs remained bioactivity and can be used 
for the treatment of secondary injury.  
We also introduced a gene silencing strategies by delivering siRNA conjugated chitosan 
nanoparticles to the spinal cord lesion. These siRNAs can specifically knockdown 
inducible nitric oxide synthase and subsequently eliminate nitric oxide induced secondary 
injury. This drug delivery system were designed to discriminate different macrophages 
which have divergent effects to spinal cord recovery and to target the specific pro-
inflammatory macrophages (M1 macrophages) instead of anti-inflammatory 
macrophages (M2 macrophages). The targeting effect allowed us more efficiently 
destruct the negatively impacted mRNA in targeted cells to improve therapeutic effects 









SPINAL CORD INJURY AND ITS POTENTIAL TREATMENTS AT A GLANCE 
 
  
1.1    Spinal Cord Injury and Animal Models in Experimental Study 
Spinal cord injury (SCI) results in a temporary/permanent motor and sensory impairment, 
also can be destructive to other organs, such as bone fracture, abnormal bladder and bowl 
movement, and cardioresperiation and cardiovascular risk.  It is not only physically but 
also spiritually affecting the livelihood of injured patients. Main causes of spinal cord 
injury usually lies in the motor vehicle accidence, falls, violence, recreational sports, and 
some are diseases related.  There are approximately 2.5 million patients who are suffering 
from the chronic paralysis. Apart from this, estimated 130,000 newly injured individuals 
occurred each year worldwide and approximately 12,000 from United State. Spinal cord 
injuries symptoms can vary depend on the type and the level of the injury. SCI usually 
can categorize into 1) complete and incomplete type of the injury based on functional 
behavior and 2) tetraplegia and paraplegia based on if the level of the injury is above or 
below the first thoracic spinal nerve. A complete injury refers to the complete sensation 
and movement loss at the lowest sacral segments of both sides of the body. The 
individuals with incomplete injury is characterized by some functions below the level of 
the injury including the lowest sacral segments. In this case, individuals might have one 
side of body function in a better condition than other. 
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The database in regarding to the injury conditions after hospital discharges since 2010 
shown that there are 40.6% of incomplete tetraplegia, 18.7% of incomplete paraplegia, 
18.0% of complete paraplegia, and 11.6% of complete tetraplegia, and only less than 1% 
of patients shown a complete neurological recovery. [1] In the laboratory researches, 
many animal SCI models were developed based on the experimental needs to mimic the 
condition of the human injury.  SCI models can be categorized to contusion, laceration, 
compression, and chemical mediated injury. Contusion model usually conducted by the 
various impactor devices, such as Multicenter Animal Spinal Cord Injury Study 
(MASCIS) contustion model, Infinite Horizon (IH) contusion model, and the Ohio State 
University (OSU) Electromagnetic Spinal Cord Injury Device (ESCID) contusion model.  
The MASCIS impactor is a device using a rod to drop onto certain level of the spinal 
cord and tracks the trajectory of the falling rod. Therefore, the same velocity, 
compression distance, and falling rate can be duplicated in each of the experiment in 
order to achieve same desired injury. Other impactors also can results in reproducible 
injury outcomes. IH contusion model is also a force based device which can displace the 
exposed spinal cord to induce the injury. The impactor produced from OSU is based on a 
slightly different technique. The main components of this device are sensitive 
electromagnetic shaker and interactive software which can control the force, slope, 
duration, and amplitude of peak displacement applied to the cord. Laceration injury is 
also frequently used in many SCI researches although it is rarely observed in the clinical 
case of human SCI. It includes partial spinal cord laceration injuries, such as focal 
myelotomy, dorsal or lateral hemisection, and complete laceration injuries, such as 
complete transaction, resection, and aspiration lesions.  The ascending and descending 
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axonal pathways can be sucessfully disconnected using these methods. The most 
common human SCI is combination of acute impact followed by the persistent or 
transient compression to spinal cord.  Many compression models using aneurysm clip or 
calibrated forceps are also developed showing a reliable, reproducible injury model 
especially with economical benefits. [2] These injury methods can successfully initiate 
certain level of locomotors and sensory loss such that we can investigate 1) the 
therapeutic efficiency of pharmaceutical agents and 2) intraspinal circuit improvement 
after grafting neural tissues or implanting biomaterial based guidance channels. The 
chemical-mediated injuries models can be induced by N-methyl-D-aspartate receptor 
(NMDA) agonists to study its associated secondary injury cascade, but may not fully 
express all the condition that may be encountered in the case of human SCI.  
Therefore, our proposing therapeutic approaches developed for SCI can based on the 
condition of compression technique initiated incomplete injuries to recreate the similar 
injury conditions in human SCI.   
 
1.2    Secondary Injury in Spinal Cord Trauma 
The primary injury is usually considered  as the initial mechanical damadge.  It can 
implicit a complicated cascade of the pathophysiological events in a spatial and temporal 
manner mainly due to vascular and biochemical effects, and this is considered as the 
secondary injury.  These changes results in a propagating detrimental cycles and 
jeopardize the potential neuronal recovery after primary injury. 
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The secondary injury is mainly characterized by apoptotic and necrotic cell death 
associated events. SCI triggers the resting and infiltration of immune cells to release free 
radicals. It eventually leads to lipid peroxidation, oxidative stress, and excessive 
production of nitrous oxide causing cell death.  These immune cells also can produce 
different cytokines and protease, such as tumor necrosis factor- α (TNF-α), interleukin 
(IL)-1β, IL-6, caspase, and calpain at the injured sites. These can also initiate and regulate 
the cell death through different signaling pathways. [3,4] The inflammation combining 
with deleterious effects of ischemia and hemorrhage by SCI can lead to a progressive scar 
formation and central cavitations (enlarged scar-encapsulated cavity).  Also, excessive 
intracellular level of Ca2+ immediately occurred after the induction of SCI could leads to 
mitochondrial damadge. [5] It also further degrade local axoplasm and results in the 
membrane breakdown. Not only the direct mechanical invasion but also the production of 
free radical, inflammatory cytokines, and protease can cause destroy or deteriate the 
integrity of the plasma membrane. It subsequently results in increased membrane 
permeability and ionic and molecules homeostasis. Moreover, oligodendrocytes/myelin 
assoicated neurite growth-inhibitory factor, such as Nogo-A, Rho-A, myelin-associated 
glycoprotein (MAG), and oligodendrocyte myelin glycoprotein (OMgp), and astrocytes / 
oligodendrocytes precursor produced various inhibitory proteoglycans, such as 
chondroitin sulfate proteoglycans (CSPG), brevican, ND-2, and DSD-1, are all showed 
also deleteriously effects to the axonal regeneration and neuronal recovery after trauma. 
Glutamatergic excitotoxicity excreted after injury can directly or indirectly via  reactive 
oxygen species (ROS) or nitrogen species (RNS) damage the cord tissue, especially to 
vulnerable neuron and oligodendrocytes which containing many glutamate receptors. 
                                                                                                                                                                                                                                                              
5 
 
Therefore, this excitotoxicity is most responsible for the demyelination of the axons. In 
addition, decreased sympathetic tone and parasympathetic myocardial effects after acute 
injury can cause various systematic changes. Vasoconstriction of spasm in blood vessel 
and irregulation of blood flow can potentially results in a ischemic environment.  
Systematic effects of hypotension and hypothermia induced neurogenic shock, 
conduction block, and spial shock were also the primary features during the secondary 
phases [6]. 
Immune system mediated secondary injury draw most of our attentions due to the 
controversial role of immune cells and its regulatory proteins in SCI and their potential 
developments. These included major types of immune cells which are microglia, 
monocytes, and neutrophils. The resident microglia and some innate immune cells exist 
in healthy environment of the central nervous system (CNS). After injury, neutrophils 
firstly response to the intrusion and immigrate to the site of injury, then, perivascular 
monocytes infiltrate into the damaged region and differentiate into macrophages.  
Activated resident microglia and infiltration macrophages, as well as neutrophils secrete 
various proinflamatory cytokines and neurotoxins and can lead to the exacerbation of the 
spinal cord.  These secondary injuries begin with hours and last for several weeks to 
months after the initial physical injury, it allowed us to have time windows to apply the 
protential treatment  to enhance neuroprotection and restore the neuronal function after 
SCI.  
 
                                                                                                                                                                                                                                                              
6 
 
1.3    Possible Treatments for Secondary Injury 
Overall, the possible treatment approaches for  sencondary injury can be accomplished by 
inhibiting the inflammatory responses and neural death, regulating the inhibitory factors 
on demyelination and scar formation, applying neuroregeration factors to spout neuron 
growth and spinal tracts, as well as cell or tissue based transplantation.  Many 
pharmaceutical agents for SCI treatment had undergone the clinical practice since 1980’s.  
Inhibition of inflammation responses and oxidative stress was extensively developed . 
NASCIS II and Japan MPSS trial based on the earlier treatment (within 8 hours post-SCI) 
of glucocorticosteroid Methylprednisolone Sodium Succinate (MPSS) unveiled the 
improved neurological and sensor recovery.  Other pharmacological compounds with 
antioxidant properties and neuroprotective functions were also developed  including 
lazaroid, cyclosporine A, and EPC-K1. [7] 
Maryland GM-1 (Monosialotetrahexosylganglioside, a major component of the cell 
membrane)  trial also achieved the similar outcomes and indicated an improved 
neurological recovery after injury, but Sygen GM-1trail which is combination of MPSS 
and GM-1treatment did not shown the beneficial outcomes.  These strategies are focused 
on controlling cell membrane disruption induced cell death in secondary injury.  Other 
approaches were also revealed similar therapeutic potentials toward delayed cell death for 
SCI treatment, for example, inhibiting proteases caspases via enforcing the anti-apoptotic 
protein Bcl-2 expression and reducing  proteases calpains by suppressing the cytoskeletal 
degradation of damaged cells. [8]  
                                                                                                                                                                                                                                                              
7 
 
Glutamate receptor antagonists (NMDA blocker MK-801 and AMPA/KA receptor 
antagonist  NBQX) have also been shown to have neuroprotective function  after SCI. 
[9,10,11] However, the trial based on the treatment of NMDA antagonists Gacyclidine 
(GK-11) for suppressing glutamate excitotoxicity did not shown any clinical 
improvement. Since the overactivation of these receptors were responsible for abnormal 
action potentialsand, they can further results in a large amount of transmitter substances 
and accompanied with electrolytic shifts, and eventually lead to the cell death or spinal 
shock after SCI.  These changes usually indicated by an increased intracellular Na+ and 
Ca+ and extracellular K+. Balancing the action potentials by inhibiting the voltage-
dependent channels could also be the potential approaches to limit the neural dysfunction 
and its damages. Sodium channel blocker Tetrodotoxin have shown a functional recovery 
after SCI, but riluzole did not have a significant clinical improvement. Calcium blocker 
Nimodipine can reduce SCI initiated ischemia. [12] 4-aminopyridine (4-AP), as 
potassium channel blocker, aims to restore the conduction properties of demyelinated 
axons. It has been shown promising outcomes for motor and sensory improvement as 
well as voluntary bowel controls.  [13,14]  
Many investigations also focused on enhancing the axonal regeneration and neurite 
promoting by either applying  exogenous neurotrophic factors or limiting the inhibitory 
factors and unpermissive extracellular matrix that responsible for inhibition of neurite 
outgrowth.  Nerve growth factors (NGF), [15] neurotrophin -3, [16] and 4/5 (NT-3, NT-
4/5), brain-derived neurotrophic factor (BDNF), [17] glial cell line-derived neurotrophic 
factor (GDNF), cilliary neuronotrophic factor (CNTF), and basic fibroblast growth factor 
(BFGF) were the most common neurotrophic factors used for sprouting and regeneration 
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in different cell type and locations. Many growth inhibitory signals occurred in SCI has 
been proved to associated with the Rho singaling pathway and Rho associated protein 
kinase (ROCK). The activation of Rho signaling pathway can disrupt or collapse the 
cytoskeleton structure of the nerve fiber growth cone. ROCK-inhibitor Y-27632, fasudil 
(HA-1077) , the protein p21CIP1/WAF1, or genetic deletion of the ROCK isoform were 
various approaches developed to eliminate the ROCK production and to promote 
corticospinal tract regeneration and locomotors improvement.  A growing strength on 
targeting protein kinases are developed as treatment in many preclinical studies.  Apart 
from Y-27632, SB203580 and TDZD-8, as potential therapeutics to inhibit  p38α-MAPK 
and glycogen synthase kinase 3 (GSK-3), were also investigated in clinical study for SCI. 
[18] Moreover, directly targeting Rho pathways using Rho specific siRNAs, C3 
transferase treatment, and Rho pathway antagonists Cethrin also addressed the similar 
results. Many myelin/ oligodendrocyte -derived growth-inhibitory proteins (Nogo-66, 
amino-Nogo, MAG, and OMgp)  were also received the attention during the SCI 
treatment since they can activate Rho signalling  to inhibit the neurite growth. The 
blockage of other  Rho activator, for example CSPG, versican, and NG2 via 
chondroitinase ABC, ibuprofen,  and indomethacin treatment can also promote neural 
regeneration.  Suppression of the inhibitory protein activity of NoGo by using IN-1 
antibody or siRNAs strategies has been shown to support the outgrowth of axonal tracts.  
[19] However, genetic deletion of myelin-associated glycoprotein (MAG) did not shown 
the significant regeneration of retinal ganglion cell fibers and corticospinal tract.   
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Some naturalling occurred molecular, such as cyclic adenosine 3'5'-monophosphate 
(cAMP), [20] inosine, [21] purine nucleoside, [22] and hypoxanthine derivative 
leteprinim (AIT-082) were also showned their neuroprotective capability. 
In many pre-clinical cases, the strategies using various stem cells, such as neural stem 
cells, schwann cells, embryonic stem cells, olfactory ensheathing cells, and bone- marrow 
mesenchymal stem cells were developed in SCI study as well.  These cells were either 
implanted or transplanted to the spinal cord for  tissue sparing, axonal regeneration, 
remyelination, and functional recoverys and showed improvments at various level. 
However, only few investigate the  the inflammation responses after SCI and treatment.   
      Computer-controlled functional electrical stimulation (FES) for SCI also extensively 
developed for strengthening the motor and sensory function of upper and lower 
extremities and limiting associated dysfunction and issues following with SCI.  In 
addition, these stimulator combined with other physical therapy approaches has also been 
shown the potentials on improvement of bone health, bladder and bowel movement,  
reducing neurophathic pain, cardioresparistion and cardiovascular dysfunation which are 
intimately related with post-SCI .  Several stimulator and its application is summarized in 
the Table1.1.  
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Table 1.1   Spinal cord stimulators development in clinical trails.  
Device Sponsor  Indication  Status 




Focus on study of upper limb intervention for  tetraplegic 
patient to generate the palmer  functions and the lateral grasp.  
Phase 
III  
FES cycling (RT300-SL ) 
/FES Stepping (RT-600)          
Hugo W. Moser 
Research Institute at 
Kennedy Krieger, Inc. 
Low level electrical currents is applied to the leg and buttock 
muscles to initiate muscles contract and produce the motion of 
the legs. Also, to improve CNS growth factors release and 
reduce the inflammatory at spinal cord.       /To increase motor, 





FIRSTHAND System Department of 
Veterans Affairs (VA) 
Somatosensory stimulation to generate functional movements, 
such as enhancing pinch strength and  upper extremity acitivity.   
Phase I/ 
II 
IST-16 (16 channel 
implanted stimulator-
telemeter) 
Case Western Reserve 
University; NIH; VA 
Surgical implant multiple contact peripheral nerve electrodes to  
to excite muscles in order to move paralyzed muscles, facilitate 
standing duration, stepping, and balance.  
 
Transcranial Direct 
Current Stimulator  
Beth Israel Deaconess 
Medical Center 
Relieve migraine pain.  Phase 
II 
Ness H200 University of 
Pittsburgh 
To aid movement and stimulate the nerves that supply 





Chang Gung University To study the effect of fast continuous passive motion on the 
reversing adaptation of human paralyzed muscle after SCI. 
 
Neural Prosthetic 
System 2 (NPS2) 
Richard A. Andersen, 
PhD 
Brain- controlled medical device, any movement plans can be 
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1.4    Biomaterials in Spinal Cord Injury Studies 
Many biocompatible natural and synthesic materials based plantforms were developed 
not only as a nerve guidance channels or structure surports,  but also can be used for drug 
delivery tools for SCI repair. Due to the complexity of spinal cord bioenvironment, the 
spinal-blood barriers cause the challenge for nanoparticle (Np) based systematic delivery. 
Therefore, more therapeutic investments are focused on using implantable platforms for 
long lasting medication therapy in SCI studies. [23] The platforms mainly include 
hydrogels, electrospuned fiber mesh, and porous scaffolds and can be made of either 
degradable or non-degradable  materials. The most common degradable natural materials 
used in spinal cord are collagen, hyaluronic acid, chitosan, agrose, fibrin, fibroin, and 
poly (β-hydroxybutyrate), and degradable synthetic materials are poly (lactide) and 
glycolide (poly (glycolide-co-lactide)) (PLA-PGLA),  poly (ε- caprolactone) (PCL). They 
are characterized by less cytotoxic effects and well supporting to the cell adhesion and 
connection. They also featured of a  lower risk of nerve compression if their degradation 
rate is at similar pace of the regenration of  the nerves. However, unpredicted 
inflammation initiated by the debris of these materials could jeopardize the theraupeutic 
effects.  When the integrity of the matrices is highly demanded, non-degradable synthetic 
materials, such as poly (2-hydroxyethyl methacrylate) (PHEMA), poly (3,4-
ethylenedioxythiophene) (PEDOT), and poly[N-(2-hyroxypropyl 
methacrylamide)(PHPMA) are more appropriated to use when safety of these materials 
were established. The special properties of synthetic material are that they can be simply 
modified and utilized varying to the application requirements. One special electrical 
sensitive polymers were also received many attentions. Polymer poly(tetrafluoroethylene) 
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(PTFE), polyvinylidene fluoride (PVDF), PEDOT, and polypyrrole (Ppy) are commonly 
investigated because they are compatible to neural tissues and can enhance the neural 
growth and drug release when expose to electrical stimulation. [24] See more details in 
chapter 2.1.1.  
The nanoparticles mediated systemical drug delivery were also developed althrough 
under the challenge of spinal-blood barriers. Delivery strategies by enhancing drug 
targeting showed promising  outcomes to solve this issue. Ferulic acid and glycol 
chitosan synthesized Nps can be delivered to lesioned spinal cord through systemical 
administration and result in neuroprotection. [25] The direct injection of nanoparticle 
suspension into the injury site of spinal cord can also be used to bypass the spinal-blood 
barriers and efficiently deliver the drugs. Directly inject glial cell line-derived 
neurotrophic factor loaded PLGA Nps to the damadged spinal cord can promote neural 
survival and functional recovery.[26] In addition, some material itself in a nanoscales, 
such as self-assembled monomethoxy poly(ethylene glycol) -poly(D,L-lactic acid) 
diblock copolymer and poly(ethylene glycol), also showed beneficial results to reduce 
lesion and inflammation, or repair damadged nerve membrane. [27,28] During this 
nanoparticle administration, the size, shape, and surface charge of the nanoparticles can 
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1.5    Goal of Current Study 
Broad and brief review of existing issues and solutions of SCI described above allow us 
to have a general understanding during SCI, especially for secondary injury studies. Our 
goal and primary contribution in this work is to focuse on exploiting the potential 
approaches based on polymer materials drug delivery strategies to eliminate the noxious 
molecules initiated by various glial cells after SCI. We included microglial cells and 
macrophages in vitro study, and reactive astrocytes in vivo study. First, we modulated the 
Ppy platform based on structure and synthesis to optimize the local drug delivery by 
maximizing the drug loading capacities of Ppy.  Especially, we are firstly introduce the 
non-invasive electromagnetic generator to initiate the chemical and mechanical 
alternation of conductive polymer Ppy for remotely controlled drug release (details 
described in Chapter 2, 3, and 4).  Second, we developed a chitosan Nps associated 
siRNA gene silencing strategies with specific targeting effects to pro-inflammation 
macrophages (M1). This targeting strategy is the first time to discriminate different 
macrophages subsets during drug delivery for neuroinflammation inhibition efficiency 
after SCI (details described in Chapter 5 and 6).  




POLYPYRROLE DRUG RELEASE  




2.1    Introduction 
2.1.1    Overview of Conductive Polymers in Neuroscience Study 
Conducting polymers characterized by high electronic conductivity, electrochromism, 
charge storage capacity, and electrochemically controllable ion exchange capacities have 
been exploited  in various engineering applications such as high-power supercapacitors, 
[29] batteries, [30] fuel cell, [31] anti-corrosion coatings, antistatic coatings, [32] 
shielding interferences, [33] sensors, actuators, and synthetic receptor. [34] In 
neuroscience study, many conductive polymers, for example, polyaniline, polythiophene, 
especially PEDOT and Ppy are primarily used for nerve guidance conduits due to their 
biocompatibility and high conductivity properties.  Ppy, as the archetype of electronically 
conducing organic polymers, have especially been exploited due to: 1) the fabrication of 
Ppy is simple and can be accomplished in both aqueous and non-aqueous conditions; 2) 
Redox activity of Ppy can be protentially used for various application, especially for drug 
delivery of our interests; 3) Ppy in the oxidized state is inherently stable for long storage 
times as long as the material is keep away from oxygen and humidity; 4) Most 
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importantly, different nature of Ppy dopant or counterions can influence Ppy 
characteristics and further expanded or improved its applications.  
Conductive Ppy has especially been used as a substrate to support the interaction and 
connection of nerve cells in many studies. [35] (Polycaprolactone (PCL) fumarate 
synthesized with Ppy enhanced cell attachment, proliferation, and neurite extension. [36] 
This result also supported by Paul Geoge et al where neurons and glial cells become 
enveloped and grew through the implants of polystyrene sulfonate (PSS) or sodium 
dodecylbenzenesulfonate (NaDBS) doped Ppy. [37] Neurites outgrowths from PC-12 
cells have also been observed when NGF electrically released from its originally 
conjugated Ppy scaffold. [38] Electrical stimulation to Ppy films in PC-12 cells, Dorsal 
Root Ganglia, and Schwann cells culture results in a significant increased neurite lengths 
compared to the ones without stimulation.[39,40] In vivo studies, Ppy implants showed 
its connection to the spinal cord tissue without increased inflammation responses; [41] 
and  also suggest motor recovery and improved somatosensory evoked potential 
conduction after implantation of Iodine doped Ppy into transected rats spinal cord. [42]  
In neurology, many medical devices have been developed to record electrophysiological 
activity in neural circuit and/or to support nerve conductance by neurostimulation.  
Developing biocompatible electrodes are very important because these electrod 
component in many of these devices can result in invasion to the tissues during recording 
and stimulation. Conducting polymer coating as neural tissue-electrode interface has been 
a promising tool to offer effective long-term performance of electrode implants.  They are  
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featured of relatively high charge storage densities but low impedance, therefore, can 
optimize the electrode-tissue communication. 
 
2.1.2    Electrochemistry for Polypyrrole 
2.1.2.1    Electropolymerization of Polypyrrole 
The proposed mechanism of Ppy polymerization starts with a slow neutral monomer 
oxidation to form a pyrrole cation radical. The reaction then followed by the coupling of 
radical cations that generate different resonance forms, fast deprotonation, and 
aromatization process to form a dimer. The chain growth then propagates by preferential 
coupling with monomers and/or dimmers and continues until the charge on the polymer’s 
backbone is incorporated with counterions. These counterions can maintain 
electroneutrality of the polymers when positive charges accrue along the polymer 
backbones. This electropolymerization process is based on the radical-radical coupling 
mechanism and illustrated in Figure 2.1. [43] 





Figure 2.1  Polymerization of Ppy. 
 
                                       
 
Figure 2.2  Neutral, Polaron, and Bipolaron state of Ppy. 
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2.1.2.2    Doping and Releasing Processes of Polypyrrole 
How does the Ppy conducting organic polymer become conductive? First, we need to 
understand that how hundreds of inorganic substances can become conductive. This is 
through a process called electronic doping: the substances can be conducted by addition 
of impurities, that can be accomplished by giving electrons to or accepting electrons from 
the nonconducting form of the substances. Conductivity in the conducing organic 
polymer Ppy is related to the configuration of alternative single and double bond along 
the polymer backbone (See Figure 2.2). Every bond contains “s” bond and every double 
bond contains “p” bond. The introduction of voltage potentials and dopant ions to the Ppy 
allows the displacement of the weakly bonded electrons in between the stronger double 
bonds, resulting in the conductivity of this material. Therefore, we can say, Ppy need to 
be “oxidatively” or “reductively” doped in order to be conductive.  
In our study, we conducted drug incorporation experiment based on the characteristics of 
Ppy oxidation as it is the most common mechanism in many drug delivery studies. The 
oxidation process develops cation along with the polypyrrole backbone, and 
concomitantly yields a local deformation which due to a geometrical change in every four 
pyrrole units. These processes constitute a “polaron” (Figure 2.2 B) and combinations of 
polarons pair can form “bipolarons” (Figure 2.2 C) during further oxidation process with 
higher charging levels. Polarons and bipolarons are the dominant charge carriers by 
transport charges along the segment of conducting polymer chain. The conductivity of 
Ppy can be reflected not only by charge migration but also the hopping charges of the 
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carriers from chain to chain. In sum, the mobility of charge carriers and the amount of 
charges in polymer chain are important for Ppy become conductive. [44,45,46]  
Here, I need to point out that redox activity of conductive polymers Ppy not only involve 
mass and resistance charges but also electron transitions, and Ppy electrochemistry 
processes can be accomplished by only involving electrons. During oxidation of Ppy, 
when certain level of positive potential is applied, electrons are removed from the 
backbone of the Ppy, thus negatively charged dopants or couterions are taken up and can 
be incorporated to the Ppy structure. These dopants compensated with the positive 
charged sites on the polymer backbone and reach electroneutrality of Ppy. On the other 
hand, when a negative potential is applied and reducing it, the anions or anionic 
molecules can be expelled (or “undoping”) as there is a loss of electrostatic attraction to 
the Ppy. (See Figure 2.3 A) Apart from the expulsion of these anions, reduction process 
can also involve the incorporation of cations. Therefore, both negative or positive 
charged drugs can be ingress or expulsed to compensate the resulting charges along the 
polymer chains.  In our case, a anionic drug DEX can synthesize with Ppy at the oxidated 
state and released at the reduced state of Ppy. 
Additionally, the oxidation-reduction action of Ppy can provoke mechanical effects such 
as swelling and de-swelling of the conductive polymer materials along with the ionic or 
small molecules fluxing in or out of the polymer structures. [47] 
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Figure 2.3  Redox reaction and overoxidation of Ppy. Redox reaction of Ppy for 
conjugation and releasing of Anionic (A) and Cationic (B) molecules and overoxidation 
of Ppy (C).  
 
2.1.2.3    The Effects of Different Parameters During Eletropolymerization 
The electrochemical approach for making electroactive materials depends on many 
parameters. For example, applied potentials, current densities, substrates, dopant, doping 
level, solvent, electrolyte, concentration of polymers, electrodes, even temperature and 
pH can influence the outcomes of polymerization of polypyrrole.  
Doping level represents the average positive charge per pyrrole ring. In general, the 
oxidation level of Ppy is at 0.25-0.32 per pyrrole unit which is one anion for every 3 to 4 
pyrrole units, which can be influenced anion types and its charges. [48]  However, at high 
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doping levels which might be caused by the application of an excessive level of anodic 
electrode potential, Ppy can be overoxidized due to trace water or other nucleophiles, 
such as OH- attack causing irreversible changes in the polymer’s chemical structure. (See 
Figure 2.3 C) This interruption of Ppy structure could lower the intrinsic conductivity of 
the polymer and make Ppy loose the capability of electrochemical activity. Thus, Ppy 
would not be able to release the drugs as described in 2.1.2.2. Since conductivity of Ppy 
at high doping levels is dramatically decreased, we control the level of potential at range 
of 0.8-1mV during Ppy synthesis, and -0.1mV for Ppy drug releasing.       
The substrates of where Ppy will be deposited during electropolymerization also 
determine the characteristics of Ppy. Many materials can be used as the substrates, such 
as glassy carbon, gold, indium-tin oxide coated glass, platinium, titanium, and aluminum. 
[49] Some substrate materials works less efficient than others, for example, when Ti, Fe, 
and Al are used as substrate, it results in a increased oxidation potential of pyrrole. In our 
experiment, we select the indium-tin oxide coated glass as substrate for flat Ppy due to its 
strong structure support and its conductivity. Also, since gold materials feature of high 
conductivity and non-toxicity , evaporated gold base was used as substrate for Ppy 
nanowire synthesis. 
The resulting electrochemical properties of Ppy is also depend strongly on the synthesis 
medium where polymer prepared during electropolymerization. One study indicated that 
interaction of counterions melanin in Ppy and various components in the synthesis 
medium. It also indicated that medium containing sulfate, phosphate, or chloride can be 
responsible for ion dynamics in Ppy films.[50] 
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The dopant used for Ppy electropolymerisation can highly influence the characteristics of 
Ppy film and have been widely discussed in different literatures.  In summary, the 
counterions should be chemically inert, very soluable in the monomer contained synthesis 
solution, and electrochemically more stable during oxidation-reduction process than the 
monomer itself (in our case is pyrrole).  Curtin et al indicate that the anion preference of 
Ppy is I->Cl->Br->ClO4- ,  [51] which could arise from the buffer salts, such as I2, BF4, 
FeCl3, and perchlorates. Much of research also reported aromatic sulfonate variants are 
good candidate as dopant for Ppy polymerization, especially for application as neural 
interfaces. These include PSS, sodium benzenesulfonates (BS), and para-toluenesulfonate 
(pTS) dopants. Moreover, various biological dopants, such as laminin peptide sequences, 
neurotrophins, hyaluronic acid, fibronectin fragments, human serum albumin, and 
polysaccharides, can also be immobilized into the Ppy to enhance cell proliferation and 
differentiation in biomaterial tissue engineering studies. [52] 
 
2.1.3    Conductive Polymer Based Drug Delivery System 
To successfully delivery the drugs using a Ppy platform, the characteristics of the drugs 
themselves are also critical for the application. To design an efficient drug delivery 
system, the size of the dopants can influence the incoroporation of the drug into Ppy or 
their release from Ppy. Matrix Maria Hepel1et al reported that melanin (a bulky 
molecule) is irreversible after incorporation into polypyrrole, whereas the small chloride 
ions can be easily released from polypyrrole after conjugation. [50] However, one study 
described that despite the fact that nicoside has a lower molecular weight compared to 
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naproxen, it cannot be released  during the potential cycling of Ppy. This result indicates 
that size is not the only parameter that should be considered during the selection of the 
drugs for Ppy based drug delivery system.[23] 
The charge of the drug molecules is usually associated with its pKa value and it is  
especially important to Ppy mediated drug delivery. This drug delivery system is not only 
able to release the anionic drugs, but also can successfully achieve the delivery of 
cationic and neutral drugs.  As described previously, anions are incorporated into the 
polymer to balance out positive charges initiated during oxidation.  When immoblised 
larger sized anionic dopants (e.g. melanin, PSS, pTS) with Ppy, cations or cationic drugs 
can be incorporated into Ppy, but during reduction instead of oxidation, and then released 
during oxidation. The study of chlorpromazine conjugated Ppy/melanin films has 
provided more insight. The mass of chlorpromazine in Ppy was increased during 
reduction and decreased in concomitant with the oxidation when evaluated by 
electrochemical quartz crystal microbalance, indicating the egrass and release of cationic 
drug, chlorpromazine. [50] Many studies of dopamine release used immobilized PSS 
with Ppy and also successfully accomplished the cationic small molecules delivery.  
Similar mechanisms also applied to incorporation and releas of NT-3and BDGF with 
immobilized molelcules pTS in Ppy. The detailed mechanism of cationic drug delivery is 
the same as that of anionic drugs by using electrostatic forces with slight differences as 
shown in Figure 2.3 A and B. Novel strategies have also been developed to help 
incorporation of neutral drugs, such as N-methylphenothiazine by using anionic dopant β-
cyclodextrins prepared Ppy films and achieved by encapsulation drugs into the 
hydrophobic interior of  β-cyclodextrins. [53]  
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2.1.4    Synthesis Techniques for 3D Nanostructure 
Compared to 2D structure, 3D structured polymers showed promising results to load 
larger amounts of therapeutic agents, especially useful in the treatment of chronic 
medical conditions. Many polymer nanostructures are well developed, such as nanowires, 
nanotubes, opal structures, and inverted opal structures. The template method is 
considered to be the most convenient for nanostructure development.  For example, 
porous polycarbonate and porous anodic alumina membrane are typically used as 
templates for nanowire growth.  The formation of pores in the template is related to either 
1) dissolution of the oxide to form pores  or 2) self-organized anodization which 
generally performed by different strong acidic electrolytes. Unlike PANI nanotubes 
which formed along with phenazine-based aniline oligomers spontaneously produced 
internal template, Ppy nanotubular growth need an external template. It could be 
generated using coating on hard template method, that is, placing insoluble inorganic 
nanofibres, such as manganese (IV) oxide, titanium (IV) oxide into the synthesis 
solutions during oxidation process, then dissolving the template to form nanotubes. [54]  
Its formation also can based on the self-assembling of some dyes, such as MO, acid blue 
AS, rhodamine B, Prussian blue, or methylene blue. The surfactant characteristics which 
combine both hydrophilic and hydrophobic moieties in these dyes, allows them to form 
supramolecular structures.  Other 3D geometric structure of Ppy are also exploited, for 
example, Luo and Cui synthesize Ppy over polystyrene beads deposited electrode, and 
formed a 3D structured polymer porous film after removal the beads. [55]  
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In our study, polypyrrole nanowires (PpyNWs) were manufactured based on the simple 
template technique using anodic alumina membrane. The modulation of the geometric 
structures of Ppy to nanowire shape can maximized the drug incorporation and can 
release drugs in relatively longer time.   
 
2.2    Method and Materials 
2.2.1    Template Preparation for Polypyrrole Polymerization 
Indium tin oxide (ITO) glass slides with 5-15 ohms resistivity (Delta Technologies, CO) 
were used for fabrication of flat Ppy. They were washed with acetone, ethanol, and then 
Milli-Q water by incubating glasses with each solution for 30 mins at an ultrasonic bath. 
For PpyNWs experiments, anopore inorganic aluminum oxide membrane (AAO) with 
0.2μm pore size and 60μm thickness (Whatman) were used. The AAO templates were 
coated with gold at thickness of  100 nm on one side using a Varian E-beam Evaporator. 
Then, they were stored in a dry oven prior to use.  
 
2.2.2    Fabrication of Dexamethasone Doped Polypyrrole Carriers 
One synthesis solution was prepared by mixing 0.2M pyrrole (Py, Sigma), 0.025M 
dexamethasone 21-phosphate disodium salt (DEX, Sigma), 0.05 M 10 nm NanoXact 
spherical gold nanoparticles (AuNps, NanoComposix, CA) together.  For comparison, 
0.2M pyrrole, 0.025M DEX, 0.1M Poly (3,4-ethylenedioxythiophene)-
poly(styrenesulfonate) (PSS, Sigma) was also prepared by gental mixing. Prepared AAO 
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templates were subsequently incubated into each of solution mixtures for 30 minutes 
before PpyNWs electropolymerization. This procedure allow the Pyrrole monomers, 
drugs, and other systheis components (either AuNps or PSS) diffuse into the pores of the 
template.  Cleaned ITO slides or AAO templates were connected to the working electrode 
from a CH Instrument model 604 electrochemical workstation with a platinum counter 
electrode and a Ag/AgCl reference electrode placed in the synthesis solution. The 
electropolymerization of DEX doped Ppy was then performed using a constant potential 
at 1V. This constant potential is cotrolled by potentiostat device in the electrochemical 
workstation, it will be briefly called potentiostat stimulation in the later content. 
Following polymerization, the final films were rinsed thoroughly with Milli-Q water. At 
end, the AAO templates will be removed by incubation in 3M sodium hydroxide. The 












Figure 2.4  PpyNWs fabrication processes. The figure at far left is an illustration of the 
AAO template. Next step showed one-side gold coated template. The third step 
demonstrate the  diffusion of pyrrole monomer, AuNps or PSS, and DEX into the porous 
column of the template. The fourth step is formation of DEX doped Ppy after 
electropolymerization process. The far right figure indicate the removal of AAO 
templates and free standing PpyNWs structure.  
 
2.2.3    Morphology of Polypyrrole Nanowires  
Imaged by Scanning and Transmission Electron Microscopy 
Ppy samples were prepared by first sputter coating with platinum for 60 seconds. SEM 
images were taken with a FEI NOVA nano SEM field emission scanning using ET and 
TLD at high vacuum at an accelerating voltage of 5 kilovolts. TEM images were taken 
using a FEI/Philips CM-10 Transmission Electron Microscope, operated at 100 kilovolts; 
A 200µm condenser aperture; and 70µm objective aperture. TEM images were captured 
by a SIA L3-C digital camera. 
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2.2.4    Electromagnetic Stimulation  
The set up of electromagnetic stimulation was illustrated in Figure 2.5. More details are 













Figure 2.5  Stimulation scheme for the application of EMFs.  (A) The top illustration 
shows the setup of EMF generator during the stimulation. The stimulator is connected to 
a circular wire-wound coil. A standard cuvette containing DEX doped Ppy film was 
placed in the center of the coil.  Left inset describes the dimensions of the coil, where 
Height(H) is 1.2cm, Length(L) is 3.8cm, and Width(W) is 3.0cm. The recordings in B are 
probe measurements of the magnetic fields (MF) and electric fields (EF) at the center of 
the coil, with ~ 36 Gauss and ~ 4000V/m respectively. The insets demonstrate the 
idealized waveforms for both MF and EF based on the input square pulse stimulation 
regime.  
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2.2.5    Drug Release 
Both potentiostat electrical stimulation and EMF stimulation were used to release DEX 
and these two methods are described in more details in CHAPTER THREE. In former 
cases, the procedure is similar to the electropolymerization process with three electrodes. 
The stimulation is potentiostat device controlled constant potentials and the DEX 
conjugated Ppy films was linked to a working electrode and emerged in PBS solution. 
Then, a constant voltage of - 0.1V was applied for five hours using electrochemical 
workstation. The DEX conjugated Ppy platforms were also stimulated by EMF generator 
illustrated as Figure 2.5 which depicts the experimental set-up and the essential 
components of the EMF stimulation system. Before conducting the drug releasing, the 
Ppy samples were placed into PBS contained cuvette and this cuvette was then positioned 
in the center of the coil without any physical contact. The coil was energized with an 
asymmetrical square wave pulses and remotely trigger drug release from Ppy. The 
supernatants were subsequently collected after 1, 3, and 5 hours of stimulation.  
In addition, different Ppy compositions used for polymer synthesis were also tested and 
compared. All experiment were last for 16 days with EMF stimulation. The sample 
solutions were collected at 1, 3, 5, 7, 10, 13, and 16 days after continuous EMF 
stimulation.  
All collected aliquot samples were analyzed by a UV-Vis Spectrometer at 242nm 
wavelength. A calibration curve of DEX (y(OD)=23.8x-0.04) was used to calculate the 
amount of released drugs.  
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2.2.6    On-Demand Dexamethasone Release  
To determine the controlabiliy of EMF stimulation to Ppy drug release, “on and off” 
experiments were performed on PpyNWs with AuNps components. The recordings were 
begun after 10 hours of stimulation by the EMF to avoid the robust release at first couple 
of hours. Pulsed EMF stimulation was turned on for 2 hours and turn off for 2 hours. This 
regimen was continued for four cycles for each sample. 
 
2.2.7    Temperature Effects on Drug Release  
To test if the release of DEX might be influenced by the heating during the stimulation, 
we placed the DEX doped flat polypyrrole templates within a incubator at 37℃. This 
temperature was slightly higher than the ambient temperature in the vicinity of the active 
coil, which was measured to be about 30℃.  
 
2.2.8    XPS Analysis 
Ppy samples about 0.5-1.0cm2 were prepared and submitted for XPS analysis.  The 
surface chemical composition of the samples was analyzed by X-ray photoelectron 
spectroscopy (XPS) using a Kratos Axix Ultra DLD spectrometer. The spectra were 
collected using monochromatic Al Kα radiation (1486.6 eV). The survey and high 
resolution spectra were obtained at the constant Pass Energy mode with the pass energy 
of 160 eV and 20 eV respectively (survey 1 eV/step; high resolution spectra 0.05 
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eV/step). A built-in Kratos charge neutralizer was used. Data analysis was performed 
with CasaXPS software version 2.3.12. 
 
2.2.9    Statistical Analysis 
All data are shown with standard error of the mean ( + SEM). Independent Student’s t-
test and one way ANOVA followed by Tukey Post Hoc test were used to determine 
statistical significance. Significance was determined by a P-value < 0.05.   
 
2.3 Results 
2.3.1 Structure of Polypyrrole Nanowires 
Nanowire architecture was imaged by SEM and TEM and illustrated in Figure 2.6 and 
2.7. Since polymers thickness can be easily controlled during electropolymerization, the 
growth of (or length of) PpyNWs can be vary with the deposition time during synthesis. 
1300-1400 seconds of deposition time can achieve approximately 10μm long PpyNWs 
(Figure 2.6 A) while shorter lengths were completed in a faster deposition times. The 
commonly used deposition time in our study is at 200-300 sec and it can form PpyNWs 
structure as showed in Figure 2.6 B. All the PpyNWs showed as free-standing vertically 
aligned conformation. For PpyNWs with AuNps composition, the distribution of the 
AuNps within the polymer bulk were indicated in Figure 2.7 A and B.  
 
 




Figure 2.6  Scanning Electron Micrograph of PpyNWs. (A) Scanning Electron 
Micrograph showing a top view of polypyrrole nanowires (200nm diameter and ~10μm 
length) with longer deposition time. (B) A similar micrograph where showed a 200nm 
diameter and ~ 500nm long PpyNWs synthesized in a shorter time.  Scale bar in 









Figure 2.7  Transmission electron micrograph of PpyNWs with inclusion of gold 
nanopartilces.  (A) Transmission electron micrograph of PpyNWs. The dark regions are 
the accumlation of AuNps in the Ppy. (B) showed details of gold nanopartilces in each 
individual PpyNWs. These wires range from approximately 500nm to 2000 nm in length, 
and ~200 nm in diameter. Scale bar in A=2 μm; and in B = 0.2 μm. 
 
2.3.2    Comparisons of Drug Release 
Drug release profile of the PpyNWs compare to conventional flat Ppy films are shown in 
Figure 2.8 A, B, and C.  




Figure 2.8.  DEX release using various Ppy platforms and stimulation methods.  (A) The 
DEX release using either constant potentials (protentiostat stimulation) or EMF 
stimulation from both flat Ppy film and PpyNWs. The releasing time were tested for five 
hours. (B) Comparison of DEX release with different synthesis compositions (AuNps vs. 
PSS dopant). All experiments were applied with EMF stimulation for 16 days. (C) Active 
(EMF stimulation) vs. Passive (no stimulation) for both flat Ppy films and PpyNWs. (D) 
"on" and "off" EMF experiment to test the DEX release from PpyNWs-AuNps when 
response to the stimulation. Higher concentrations of DEX were generated with EMF 
stimulation whereas a smaller amount of DEX was detected at the absent of EMF 
stimulation. * p < 0.05; ** p < 0.01; and *** p < 0.001. 
 
                                                                                                                                                                                                                                                              
36 
 
Figure 2.8 A reveals the results of DEX release over a five hour period of stimulation. 
For flat Ppy, potentiostat mediated stimulation was not significantly different from that of 
EMF stimulation. Although there is no statistical difference beween EMF stimulation and 
potentiostat mediated stimulation in the case of PpyNWs, there was more apparent DEX 
release when using EMF stimulation. Also, upon the exposure to EMF stimulation, there 
was a statistically significant increase in the DEX release of PpyNWs compared to flat 
Ppy film (*p < 0.05). 
AuNps embedded Ppy either in flat Ppy films or PpyNWs also showed increased DEX 
release when compare to the PSS doped Ppy films.  At 1, 7, and 16 days, these 
differences were by almost double for both Ppy platforms (*p < 0.05 between PpyNWs 
and **p < 0.01 between Flat Ppy). Also, the results of flat Ppys only showed  marginal 
release of DEX (<0.5mg/cm2) from flat Ppy films. In contrast, PpyNWs showed a very 
significant enhancement of DEX release. (At day 1 and 16, **p < 0.01, and at day 7, 
***p < 0.001 between AuNPs; At day 7 and 16, **p < 0.01 between PSS study; Figure 
2.8 B). The groups without EMF showed relatively small amount of DEX diffusion,  and 
it was below 0.11 mg/cm2 for PpyNWs and 0.3mg/cm2 for flat Ppy films on the last day 
of recording. This reveals a extrodinary DEX release occurred after EMF stimulation 
compared to without EMF stimulation. (At day 1, **p< 0.01, and at day 7 and 16, ***p < 
0.001 between PpyNWs; At day1, *p < 0.05, and at day 7 and 16, ** p < 0.01 between 
Flat Ppy films; Figure 2.8 C). Further "on" and "off" switching stimulation performed by 
EMF was used to test the control of DEX release as shown in Figure 2.8 D. In such cases, 
DEX release fell off precipitously at absence of EMF stimulation, and was regained when 
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EMF coupling was applied. Such consistency over several cycles demonstrated the 
protentials to controlled drug release using this drug delivery strategies.  
 
Figure 2.9  DEX release profiles of flat Ppy as a function of temperature and its 
comparison to that of with and without EMF stimulation. *p< 0.05, ** p < 0.01. 
 
2.3.3    The Influence of Temperature Elevation on Drug Release 
According to the results from Figure 2.9, there is some increased level of DEX passive 
release under the elevation of temperature (37oC) compare to the samples at room 
temperture without EMF stimulation. However, no statistical difference was observed 
until 13th day whereas the significant statistical difference occurred from day 1 when 
using EMF stimulation compared to without stimulation . Therefore, we conclude that the 
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DEX release result from increased temperture did not reach the levels of active EMF 
stimulation during the entire experiment, and are not the driving force for DEX release. 
 
2.3.4    XPS Confirmation of Dexamethasone Release 
X-ray photoelectron Spectroscopy (XPS) was used to verify the existence of DEX after 
loading with Ppy and the escape of these loaded DEX after EMF stimulation (See Figure 
2.10). XPS surface analysis was conducted on the PpyNWs before and after (16 days) 
EMF stimulation. High-resolution spectra of F 1s (fluorine) and P 2p (phosphorous) 
elements in the DEX molecule can reveal the elemental components in PpyNWs before 
and after stimulation. It can denote the presence and absence of DEX upon exposure to 
the EMF. These two elements were vanished after EMF stimulation indicating the DEX 
release after EMF stimulation. For PpyNWs-AuNps, the pre-stimulation F 1s and P 2p 
atomic percentages were 1.53% and 1.54%, respectively while the post-stimulations 
results were 0.00% and 0.17%. For PpyNWs-PSS, the pre-stimulation F 1s and P 2p 
atomic percentages were 0.60% and 1.31%, respectively while the post-stimulations 
results were 0.00% and 0.15%. 




Figure 2.10. XPS spectra for surface analysis of DEX presence on Ppy templates before 
and after EMF stimulation.  (A) Elements identification on the surface of DEX doped 
PpyNW-AuNps before (Green) and after (Red) EMF stimulation. Characteristic peaks are 
shown in this spectrograph. (B) Same recording for DEX doped PpyNWs-PSS before 
(Green) and after (Red) 16 days of EMF stimulation. Below A and B are expanded views. 
These show details of signature fluorine and phosphorous elements indicating DEX 
molecule. Note that apparent elemental signatures were observed before EMF stimulation 
and vanished after EMF stimulation, indicative of DEX release from the surface of 
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PPyfilms. The very bottom graph shows the molecular structure of DEX, with fluorine 
(F) and phosphorous (P) highlighted in red. 
 
2.4     Discussion 
In this study, we investigate the potential of polymer implantation for local drug delivery 
strategies based on the nature of implantation. We focused on the Ppy mediated drug 
delivery system from three aspects: structure, synthesis, and releasing profile in order to 
non-invasively administrate the drugs over a relative long-term. A geometrical 
modification of Ppy to 3D structure increased both surface areas and overall volume of 
the Ppy, and enhanced the possible payload capacity of these carriers. It has been proved 
that dramatically increased NGF were indicated in  a inverted opal structure ( porous) of 
Ppy compare to the flat Ppy. [56] In addition, the template assistanted manufacture of 
PpyNWs is simple and highly reproducible. A large area of PpyNWs film showed 
consistancy of vertical nanowires through entire film (See Figure 2.11). The embedded 
AuNps enhanced the strength of Ppy structure and improved its electrochemical activity 
with increased DEX release. Most important, we are the first to introduce Ppy responses 
to non-invasive electromagnetic fields and its potential use for drug delivery.  This 
approach was designed to optimize the performance of many medical devices and 
implants which require relatively long-term and stable amount of drug administration to 
very local sites. 
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Figure 2.11  High magnification of TEM image depicts the successful fabrication of 
PpyNWs through entire film. Scale bar is 50μm. 
The mechanism of DEX release from Ppy when it responsed to EMF exposure could be 
the result of single or multiple phenomenon. As we mentioned in the Introduction, Ppy 
films undergo a reduction when sufficient negative potential is applied, therefore, anionic 
drugs DEX can be expulsed to the surrounding solutions. The other potential cycling 
methods, such as cyclic voltometry and bipolar (pulsed) current stimulation (See details 
in  3.1.2), applying both cathodic and aniodic current which is similar to EMF stimulation 
have been reported and indicated that they can also successfully release drugs out of Ppy 
matrix.[57,58,59,60] Ppy conducting polymers swell during oxidation along with the 
entry of counterions into the polymers and results in a mechanical change and volume 
enlargement of the polymer. Conversely, Ppy shrinks during the expulsion of counterions 
at the reduction process. This electromechanical property is commonly used as the basis 
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of actuator, such as polymer based artificial muscles, and also existed during drug 
incorporation and releasing. In our case, the Ppy with high conductivity has more mobile 
charge carriers that can interact with the EMF. The switching of the polarity of the EMF 
produces a very short-lived, but bipolar electric field. This transitory alternative electrical 
field potentially provide the conditions for undoping of the anionic drugs from the Ppy at 
the concomitant of polymer de-swelling. According to the results,  drug release amount 
dramatically increased at the first day of release and was reduced after 5 days. This  is 
possibly due to doped Ppy fims possess high conductivity and mechanical strength, but 
this decrease during the undoping process. 
We are not excluded the possibility of the anions in aqueous solutions might move into 
the interstices of the Ppy polymer coil and exchange small sized anions or anionic drugs 
out of the Ppy films during the potential sweeping. This effect has been used to develop 
electrically switchable ion-exchanger for purification of water. [61] Bipolar current or 
heating can cause the movement or relative rapid movement of ions in the solution, 
providing the potential exchanges between anions. In this situation, certain anions in 
aqueous solution such as Cl- with a stronger electrostatic interaction might be more 
vulnerable to exchange with other anions. This ion exchange action of Ppy could 
potentially play a role during DEX release.    
pH values can also be responsible for the ion exchange abilities of Ppy.  During the low 
pH, protonation of the nitrogen increase the capacity of ion exchange, in contrast,  
deprotonation in a higher pH environment can result in reduced or even devanished 
electronic conductivity and eventually lead to the expulsion of anions. [62,63] This is not 
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likely the reason in our case since all the solutions in which Ppy placed remain a neutral 
pH value. However, the possible disruption to the weak electrostatic interaction between 
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CHAPTER THREE  
DESIGN AND SELECTION OF ELECTROMAGNETIC FIELD GENERATOR 
 
3.1    Introduction 
3.1.1   Time-Varying Electromagnetic Fields 
A time-changing electric field can produce a magnetic field, and conversely, a time-
changing magnetic field can produce an electric field. The former statement is the 
experimental basis of Ampere’s law and the latter for Faraday’s law in a time-varying 
conditions. Ampere’s Law (See Figure 3.1) indicates that a magnetic field is produced by 
a changing electric field and a current.  For time-varying magnetic field, it includes 
conduction current (for static (dc) conditions) and the displacement current.  It means that 
either true conduction current density J (A/m2) or by a time-varying of electric flux 












Figure 3.1  Ampere's Law and Faraday's Law. 
In the equation of faraday’s law (See Figure 3.1), left side indicates that a voltage is 
induced in the closed loop considered as electromotive force. Right side is the time-
changing magnetic flux penetrating the surface whose perimeter refer as contour. Here 
needs to be clarified is that Faraday’s law gives the same results for different surfaces as 
long as the contour size does not change, that is, only those magnetic field lines that 
penetrate the contour of surface contributes to flux. In sum, the faraday’s law refers to 
time-varying magnetic flux (the average of magnetic field over the area of the loop) that 
penetrates a surface bounded by contour will induce an electromagnetic force (emf) 
which is very similar to a voltage source in that contour. The minus sign in Faraday’s law 
is related to Lenz’s law providing that the direction of that induced emf will produce a 
current in contour whose magnetic field will oppose changes in the original magnetic 
field.     
In our study,  we based on this physics pheomenon of electromagnetic induction and 
custermized a electromagnetic generator where an alternating current flowing through the 
coil at a certain frequency and generates an oscillating magnetic field around the coil. 
When the coil is closely positioned to an electrically conductive material, it also induced 
Ampere’s Law :  
∮c H . dl = ∫s J . ds + d/dt  ∫s D . ds  
 Faraday’s Law: 
∮c E . dl = - d/dt  ∫s B . ds 
                                                                                                                                                                                                                                                              
46 
 
a current known as eddy current in the conductive materials. We hypothesized that this 
current can initiate the drug release from conductive polymer Ppy.   
 
3.1.2    Electrochemical Techniques Used for Polypyrrole Based Drug Release 
The most frequently used electrochemical techniques in the Ppy based drug releasing 
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Table 3.1.  Polypyrrole based drug release. 
 
Dopant  Released Compound 
(anion+/cation-) 
Stimulation Condition  Ref 
Galvanostatic: 
  (DEX)(-) Galvanic  Mg alloy  [64] 
Cathodic Potential: 
Ppy/Cl Glutamate (-) -1.0V vs SCE  [65] 
 Sulfosalicylic acid (-) -0.5,-0.8,-1V  [66] 
 Fluorescein (-) -2V [55] 
Ppy                               ATP(-) -0.6V [67] 
 Salicylate and 
Naproxene (-) 
-0.7,-0.4V [68] 
 Hexacyanoferrate (-) -0.4,<-0.6V [69] 
 DEX (-) <-0.6V [70] 
Anodic Potential: 
Ppy/biotin/streptavidin NGF +3V [71] 
Poly(N-methylpyrrole) 
/PSS 
Dopamine (+) +0.5V [72] 
Cyclic Voltometry: 
 DEX (-) -0.8~+0.9V/+1.4V [73,74] 
 ATP (-) +0.6~-0.6V [75,76] 
 Acetylsalicylate or 
salicylate (-) 
-1V [77] 
Ppy/ pTS NT-3 -0.8~+1.0V [78] 
Biphasic Pulsed Potential or Current: 
Ppy/ pTS NT-3 and BDNF(+) 
 
+/-0.5 and +/-20 mA at 





Ppy/pTS          
 
ATP(-) -0.6~+0.6V [80] 
Ppy/melamin and 
Ppy/Cl 
Chlorpromazine (+) -0.8~+0.2V [50] 
Poly(N-methylpyrrole) 
/PSS 
Dimethyldopamine (+) +0.4~+0.6V [81] 
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The potentiostat is an electronic device controlling constant potential difference between 
the working and reference electrodes.  Chemically, it refers to the flow of required 
electrons in order to maintain voltage potentials at a fixed level. In some of controlled-
potential techniques, such as cathodic potential and anodic potential listed in Table 3.1, 
bulk electrolysis coulometry is usually the most common and desirable method used to 
achieve the constant potential.  On the other hand,  a galvanostat is a device to measure 
and control the constant current flowing through the system, instead of the constant 
potential.   
Cyclic voltammetry is a potential cycling technique by changing the potentials of 
stationary working electrode linearly with time from no reaction occurred to potentials 
where reduction or oxidation of a analyst occurred. It scans potential negatively 
(reduction process) before reaching to the switching potential, and the scan reversed 
where scan potential positively (oxidation process), the voltage then swept back to 
original point.  (shown in Figure 3.2 A and B) During this potential sweeping, the current 
is measured by potentiostat device and display to a cyclic voltammogram plotted as 
current vs. potential (See Figure 3.2 B). As the summary Table 3.1 shows, there also are 
many investigations on the potential step techniques for Ppy drug delivery. In the 
potential step measurement, the applied voltage is instantaneously jumped from one level 
to another, and corresponding current were measured as a function of time. It could 
include either single potential step (Figure 3.2 C and D) or double potential step (Figure 
3.2 E and F). The former one is related to only the potential with forward step, and latter 
case is with addition of the potential that returned to a final value following a time period.  
Many stimulation methods, such as galvanostatic, cathodic potential, and cyclic 
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voltammetry,  have been successfully used to release DEX from Ppy plantforms. (Bolded 
in Table 3.1) ()These can provide as useful reference to understand the mechanism of 
DEX release. 
In our study,  we focus on a special stimulation technique: pulsed current stimulation. 
The electrical field induced by our electromagnetic field generator (See Figure 2.5) 
shares a similar pattern to that of biphasic pulsed current. The pattern of this bipolar 
current is similar to double potential step shown in Figure 3.2F) with an alternative 
polarity of potentials and current. The exact illustration was indicated at Rachael T. 
Richardson et al. [58]  
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This biphasic pulsed current generator with +/- 0.5mA current amplitude and frequency 
of 5Hz has shown a successful NT-3 release for 7 days. [78] The same generator with +/- 
1mA and frequency at 250 Hz has also indicated the potential application to produce a 
long- term releasing profile by Ppy conductive polymer. [58,59,60] The most significant 
drawback of biphasic pulsed current stimulation is that it requires the direct contact of the 
electrode with the drug-doped polymer. This is not required in our EMF method. Our 
electromagnetic generator was designed to simulate the drug release without any physical 
contact to avoid any potential invasion to tissues during clinical application.  
 
3.1.4   Electromagnetic Field in Biological and Medical Studies. 
The inductive coupling of pulsed EMF technique has revealed an emerging and 
substantial clinical application in tissue repair, dominantly in orthopedic application and 
wound healing.  A large number of studies had shown the physiological efficiency of 
electromagnetic-based clinical devices.  The majority of these investigations used 
extremely low frequency electromagnetic device exposure. Moreover, these devices have 
been shown to be physiologically effective usually up to 20 Gauss peak time-changing 
magnetic fields and up to a 150mV/cm for peak induced electric field at the treatment 
sites. For example, some studies have suggested that the combined application of 
alternating and static magnetic fields wigh low frequences might alter the binding 
kinetics and  result in the changes of ion or ligand movement in the binding site. [82] 
Pulsed EMF also has shown the potentials to exert an anti-inflammatory action, alleviate 
pain in arthritis and degenerative joint injuries. [83]  
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Not only extremely low frequency electromagnetic devices used in biological study, 
pulsed radio frequency devices were also exploited in some application.  The induced 
electric field from a pulsed radio frequency devices at orders of magnitude larger, which 
is approximately between 10 and 40 MHz. Among many biological therapeutic strategies, 
cancer treatment commonly associated with radiofrequence devices because it can raise 
the local body or tissue temperature to a desired level (effective temperature range would 
be 42-45oC) to cause hyperthermia and destroy the tumors.  The application of 
electromagnetic field in drug delivery system was commonly conducted with magnetic 
nanoparticles, or many temperature- sensitive materials. [84] These earlier studies did not 
investigate the response of conductive polymers to EMF, therefore, in our work, we 
concentrated on the action of Ppy EMF exposure and its potential applications.  
Concerns regarding the safety of EMF exposure to human body were also arised as the 
developing the EMF associated medical application. The available data from IITRI(US), 
IAF(Canada) and MKI(Japan) showed no evidence regarding to EMF related general 
toxicity, including epidemiologic studies for occupational EMF exposures and 
experimental studies for both animals and humans. In teratology studies, there has no 
results indicating decreased in fertility in male or female animals that receiving EMF 
exposures. The possible role of EMF in immunotoxicity studies and carcinogenesis have 
also been thoroughly investigated.  The results of these studies reveal that there are no 
observable deficits in lymphoid organ cellularity or histology and T or B cell function 
after exposed to the EMF field. There are few studies indicated the significant 
suppression of NK cell function, but only in female mice, not in the case of male mice or 
female and male rats.  In some biochemical based experiment, extremely low frequency 
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magnetic field (60Hz, 50 Gauss) combining with 100μm H2O2 showed a decreased 
number of viable cells after 24 hours exposure time, however, there is no Bax and Bcl-2 
protein level or activation of  caspase-3 apotosis signaling were observed. [85] 
Combination of other noxious element (such as H2O2, FeCl2, or UVA) together with a 
long-term EMF exposure could generate ROS, [86,87] but not for a short time exposure. 
Zmyslony and others tested the effects of EMF with radiofrequence to the production of 
ROS and showed that the 15mins of radiofrequence exposure did not alter the production 
of  ROS.[88]  
 
3.2    Methods and Materials 
3.2.1    Configuration of the Electromagnetic Field Stimulator 
Multiple factors must be considered when designing the EMF stimulation system and 
pulse conditions. These parameters include waveform shape, pulse duration, pulse 
magnitude, duty cycle, etc.  Three-way switchable magnetic field stimulator was custom 
made for the purpose of this study. This device is an integrated system with asymmetric, 
symmetric, and pulse train three different waveform conformations (Illustrated in Figure 
3.5 and 3.6), and a professional electronics schematic is provided in Figure 3.3.  We 
chose square waveform to maximize the induced electric fields within the Ppy since that 
is the hypothesized stimulus for drug release. The coil was made of AWG 16 copper wire 
with 15 turns, and its geometry of the coil was build at the size of 3.0cm (W) x 3.8cm (L) 
x 1.2cm (H) ( See Figure 2.5). The coil was then stimulated with a pulsing regime using a 
custom made circuit. Each input pulse was only “on” long enough to saturate the coil 
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(pulse width at 500ns), and then turned off for the duration required to completely unload 
the coil (~10μS) (See Figure 3.6). Therefore, the duty cycle was approximately 4.8%, and 
other two stimulation patterns are also maintained a ~5% duty cycle. For comparison, 
sawtooth waveform shown in Figure 3.8 is also studied. This generator can be designed 
by various ways, in our case, it composes of NPN and PNP transistors show in Figure 
3.4. 
 
3.2.2    Electromagnetic Field Measurements 
Using the waveform patterns shown in Figure 3.5 as the input signal, the real time 
magnetic and electric field output from the stimulation coil were measured using high 
frequency EMC 100B (magnetic) and 100D (electric) probes (Beehive Electronics, CA).  
Probes were connected to a Tektronics TDS 2012B oscilloscope and terminated with a 
50Ω resistor. For data collection, each probe was positioned and oriented in the 
stimulation coil center for maximum expected reading. This value was taken to be the 
output probe value and converted to dBm. The recorded data points from the oscilloscope 
were imported into MS Excel in which the Fast Fourier Transform (FFT) of the 
waveforms was calculated. From the FFTs, the fundamental frequency, along with the 
output dBm power value was used with the antenna gain equation provided for each 
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3.2.3    Antenna Gain Equations  
The antenna gain equations used to convert EMF probe voltage into the corresponding 
magnetic and electric fields are as described:  
For magnetic field (100B) probe:  
Pout = 42.2 + 20log(B) + 20log(F)  
Where  
B is the magnetic flux density, in tesla  
F is the frequency of the received signal, in megahertz  
Pout is the probe output power into 50 ohms, in dBm  
For electric field (100D) probe:  
Pout = -113.2 + 20log(E) + 20log(F),  
Where  
E is the electric field strength, in volts/meter  
F is the frequency of the received signal, in Megahertz  
Pout is the probe output power into 50 ohms, in dBm 
 









































Figure 3.4  Schematic figure for sawtooth generator.  
 
3.3    Results 
3.3.1    Electromagnetic Field Characteristics. 
The real-time magnetic and electric field output waveforms at  the coil center were 
plotted in Figure 2.5. The measurements revealed that the magnetic field output was 
similar to the input field, with some oscillation noise present in the square waveform. 
FFT decomposition of the measured signal showed the fundamental frequency of the 
magnetic field was to be 3.2MHz. This converts to average peak amplitude of 36 Gauss 
when using the antenna gain equation. Moreover, the amplitude of the magnetic field did 
not vary by more than 20% within the coil. The highest field amplitudes were in the x-y 
plane at the center level of z-axis. Along the z-axis, there was a small drop-off in 
intensity as the probe was moved away from the coil center. Overall, the magnetic field 
surrounding outside the coils has weaker signals at a order of cubic decay. Therefore, all 
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Ppy drug release experiments were applied within the coil and exposed to peak magnetic 
fields roughly within the range of 25-40 Gauss.  
Similarly, the raw electric field data is also depicted in Figure 2.5. Note that the measured 
electric field corresponded to the measured magnetic field, as expected by Faraday’s law. 
The electric field waveform exhibited oscillatory behavior with sharp peaks primarily 
concentrated at the “ramp-up” and “switch off” phases of the EMF. The peak E-field of 
was measured at 4700V/m with a fundamental frequency of 65MHz. Thus, the estimated 
electric field magnitude in which the Ppy film positioned is in the 3000-5000V/m range. 
The time-averaged EMF values are lower when considering the duty cycle, and would be 
less than 5% of these values. The distance dependence of the electric field from the coil 
center is similar to that of the magnetic field.  
 
Figure 3.5  The input signal generated by asymmetric waveform stimulation. 500ns pulse 
duration were spaced 10µs apart. These pulses were in the positive direction for 200ms 
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3.3.2    Drug Release by Square Waveform Stimulation 
The geometry of the signal can highly influence how effective they create the biological, 
chemical, or physical responses. In our study, to compare the efficiency of drug releasing, 
the releasing profile of DEX conjugated flat Ppy – AuNps films using train waveform 
and symmetric waveform were also performed  (See Figure 3.6).  In both cases, pulses of  
duration were spaced 10µs apart which is the same as that of asymmetric waveform.  The 
difference is that there is no reversed stimulation in the case of train waveform.  For 
symmetric waveform, the pulses are in the positive direction for 200ms and then 
alternated to the reverse polarity for another 200 ms.  EMF measurements for these two 
waveforms were conducted as the study of asymmetric waveform. To define the most 
effective electromagnetic fields, we compared the DEX release using these two square 
waveform configurations to the results of asymmetric waveform. (See Figure 3.7).  
 
 
Figure 3.6  Illustration of input signals in the case of pulse train (left) and symmetric 
waveform (right). There is no reversed stimulation for pulse train waveform. The pulses 
in symmetric waveform have same stimulation duration (200ms) in both positive and 
negative direction.  













Figure 3.7  Comparison of DEX release from flat Ppy–AuNps films using pulse train, 
asymmetric, and symmetric waveforms.  
 
According to the results, there is no statisitcal difference between these three cases. It 
could due to the magnitude of peak magnetic field and electrical field of these two 
waveforms were similar to that of asymmetric waveform.  
 
3.3.2    Drug Release Using Sawtooth Waveform 
To optimize the drug release, we also developed an electromagnetic field generator that 
could produce a sawtooth waveform. The sawtooth waveform can be considered as an 
extreme case of asymmetric triangle waveform. The magnetic field produced on the 
wave's ramp and collapses on the wave’s cliff (Shown in Figure 3.8 left) where induced 
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the maximum level of electrical field. Since the magnitude of saw tooth pattern increase 
very sharply, it can produce a strong electromotive forces (Figure 3.8 right), but the 
polarization of electric field cannot be determined using sawtooth potential.[89]  
 
Figure 3.8  Illustrations of the input signal of magnetic field (right) and electrical field (left) 












Figure 3.9  DEX release comparision between EMF stimulator with sawtooth waveform 
(blue) and with pulsed square waveform configuration (green).  
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Increased amount of DEX release was clearly observed using sawtooth wave stimulator 
from day 1 to the end of the experiment (See Figure 3.9). However, there was no 
statistical significant difference between the square wave and the sawtooth wave at any 
point of the experiment. At day 16, the p value for statistical analysis was calculated as 
0.06 using independent student t-test with assumption of normal distribution.  A 
increased trend of the DEX released using sawtooth waveform was observed compared to 
that of the square waveform. It kept a the constant increasing level during the testing,  
indicating the excessive DEX release of each sample under sawtooth wave based 
stimulation.  
 
3.4    Discussion 
Since the cells usually are at a condition of highly conducting ionic medium, it has been 
proven that they can response to the electrical field and their biological effects are greatly 
influenced by ion displacement in the body. In general, this ion displacement occurred 
due to the peak voltage value also represented as the electromotive forces. This 
electromotive forces can be initiate at abrupt "falling " time in a given pulsed signal, 
depending on the electrical characteristics of the coil employed, the shape or waveform of 
the electromagnetic signals, and how fast the rising and falling time changes. Among 
various waveforms, both sawtooth and square signals are far more abrupt than the simple 
sine waveform.  The advantage of sawtooth pulse form is that it simultaneously contains 
various individual sine vibrations with broadest frequency and amplitude. These can 
composed of the similar frequency and amplitude of oscillating wave from cell 
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membrane. In this case, cell membrane can respond to the resonate frequency which 
similar to the cell’s natural frequency. This waveform is first introduced by Dr. 
C.A.L.Bassett and proved by FDA for the treatment of non-union fractures and assist 
spinal fusion operations. This is based on Faradays’ law we described earlier, that is: 
changes in the electromagnetic signals can induce an electrical current, and the maximum 
current induces when the magnetic flux changes most abruptly. Since the intensity of 
electric field is dissipating from the center of the coil in our case, the higher level of  
induced electrical field generated from alternating magnetic field may compensate the 
negative impacts of the distance. In this case,  the actual penetration capability of the 
induced current can be critical for this drug delivery system to be used in clinical 
applications, and it usually refers to the standard depth of penetration equation.  This 
penetration involves with several parameters. The penetration decreases when eddy 
current at a higher frequences travelling through a materials with high conductivity and 
permeability. Since redox properity of Ppy requires highr conductivity in order to release 
the drugs, we need to adjust the stimulator to larger coil size and lower pulse frequences 
in order to achieve an increased penetration of both magnetic field and current flow. 









ATTENUATION OF SECONDARY INJURY  
BY ELECTROMAGNETIC RESPONSIVE POLYPYRROLE DRUG DELIVERY 
 
4. 1    Introduction  
4.1.1    Cellular, Molecular, and Biochemical Cascades in Spinal Cord Injury   
4.1.1.1    ROS and RNS 
Collected evidences have identified that the activation and accumulation of resident 
microglia and infiltrating macrophages after spinal cord trauma can cause inflammatory 
and immune responses which can amplify the destruction. Macrophage and microglial 
cells can be activated by different endotoxins or cytokines, such as TNF-α, 
lipopolysaccharide (LPS, a component of the wall of Gram-negative bacteria), and a 
combination of  interferon γ (IFN-γ) and LPS, or H2O2. Then, they can trigger various 
inhibitory molecules, such as IL-1β, TNF-α, nuclear factor-kappa B (NF-κB), nitric oxide 
(NO), and ROS which initiates a cascade of neuropathological events and results in the 
cellular death via necrotic or apoptotic pathways. In our study, we focused on the RNS 
and ROS production due to the suppressive ability of DEX to them (See details at 4.1.2) 
and their detrimental effects to SCI. These can be used to test drug delivery efficiency in 
vitro and in vivo studies.  
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During the activation of macrophages, inducible nitric oxide synthase (iNOS) utilizes 
oxygen and electrons from nicotinamide adenine dinucleotide phosphate (NADPH) to 
oxidize the catalytic substrate L-Arginine into NO.  NO and superoxide (•O2-) are radical 
effectors of the innate immune system that helps to inhibit the growth of invading 
microorganisms. Although NO is an anti-bacterial and anti-viral effector and can protect 
the brain and spinal cord from certain infectious diseases, excessive levels of NO can also 
be toxic to neurons and could cause neuroinflammatory conditions after SCI. Many 
studies have suggested that synergistic reaction of NO and superoxide can produce 
cytotoxic molecules peroxynitrite (ONOO-) which can readily oxidize nucleic acids, 
proteins, and unsaturated lipids [90,91] causing neuronal cell death in SCI. [92,93,94,95] 
Furthermore, reactive intermediates of over-expressed iNOS are mutagenic and would 
not only lead to DNA impairment but also results in the growth of tumors in CNS.  
Suppressing ROS production also critical in SCI because they contribute to lipid 
peroxidation by attacking the cellular membranes, especially to polyunsaturated fatty 
acid, and many other macromolecules, such as protein and nucleic acid, leading to the 
neuron death. ROS usually refers to small molecules •O2-, hydrogen peroxide (H2O2), and 
hydroxyl radical (•OH) that are generated during the electron transfer process of 
mitochondria as well as the unstable intermediates during the lipids peroxidation. The 
hydrogen peroxide is generated from superoxide via superoxide dismutates. Hydrogen 
peroxide can either be converted to a strong toxic oxidant hypochlorous acid by 
myeloperoxidase (MPO) or converted to highly reactive hydroxyl radical during the 
Fenton reaction, or converted to water and oxygen becoming non-toxic when catalyzed 
by catalase and glutathione (GSH) peroxidase.  Aerobic organisms can reduce molecular 
                                                                                                                                                                                                                                                              
66 
 
oxygen (O2) in water to creat energy. During this process, partially reduced oxygen 
species are inevitably generated, such as superoxide, which is not detrimental in low 
concentrations. However, an abnormally excessive production of various ROS causeing 
an imbalance between radical generation and scavenging which will actually cause 
damage. This imbalance is represented as oxidative stress and always occurres after SCI. 
Since radicals have an unpaired electron, they can become highly reactive with any 
macromolecules and damage them by modifying their structures and/or functions.   
 
4.1.1.2    ROS and RNS   
        Associated Mitogen-activated Protein Kinases Signaling Pathways  
It has also been implicated that the cascade of secondary damages in SCI is closely 
involved with the regulation of mitogen-activated protein kinases (MAPKs) signaling 
pathways. [96]  Phosphorylation of MAPKs on a specific activation loop which contains 
a characteristic threonine-x-tyrosine motif active three principal subfamilies of MAPKs 
signaling pathway: extracellular signal-regulated kinases (ERKs), p38mapks, and c-Jun 
NH2-terminal kinases (JNKs) or stress-activated protein kinases (SAPKs). Thus, the 
initiation of the subfamily of MAPKs in the study of secondary injury after SCI was 
critical. [97,98] They especially play an important role in NO assoicated deterioraton of 
neuronal activity in the SCI. [99] Therefore, the inhibition of MAPKs family signaling 
pathway implies the physiological importance to neuronal recovery after traumatic injury. 
In a microglia-neuron co-culture condition, p38 and JNK inhibitors can partially rescued 
neurons from death after LPS challenge. [100] Also, inhibiting ERK1/2 pathway may 
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eliminate cortical neuron damage after IL-1 insults. Administration of the specific 
inhibitor of MAPK3/MAPK1 (PD98059) significantly improved motor functional 
recovery. These evidences demonstrate that the activation of MAPK highly influence the 
secondary injury after spinal cord trauma. [96] 
The activation of MAPK can be initiated by the ROS related oxidative stress, and ROS 
blocking approaches have showed the inactivation of this MAPK signaling 
pathway.[101,102] This ROS medicated activation can be due to oxidation of growth 
factors, oxidative modification of intracellular kinases, such as thioredoxin, and down-
regulation of inactive members in MAPK pathways, such as mitogen-activated protein 
kinase phosphatase 1 (MKP-1). [102,103,104,105,106,107] There is an abundance of 
literatures reporting that the activation of several MAPK families signaling pathways 
including ERK1/2, ERK 5, JNK, and p38 can be initiated by H2O2 and then generates 
ROS. 
The MAPKs have also been shown to be involved in activating many transcription 
factors and directing cellular responses to various noxious stimuli, for example, 
proinflammatory cytokines. The transcription regulation of iNOS has been reported to 
involve with JNK pathway by IFN-γ +TNF-α. [108,109] Further studies have indicated 
that the LPS or combination of IFN-γ and LPS stimulated ERK and p38 mapk cascades 
of signaling molecules regulate the induction of iNOS in glial cells. [110] Thus, we 
designed our experiment using LPS and H2O2 as stimuli to initiate iNOS and ROS via 
MAPK signaling pathway.  
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Dexamethasone, as a well-known anti-inflammation drug, has shown its successful 
regulatory effects on inflammatory responses. It has also been known to antagonize LPS-
induced JNK/SAPK pathway via inhibits the production of cytokines, TNF- α, [111] and 
partially limit the pro-inflammatory gene expression by inducing the expression of MKP-
1.[112] Suppression of NF-κB activation by glucocorticoids can result in iNOS down 
regulation in some cells line .[113] Further results indicate that the suppression of LPS 
activated MAPKs by dexamethasone blocks the iNOS expression and ROS production. 
[114] The different concentration of dexamethasone between 0.1 to 10μM has been 
proved to inhibit the expression of iNOS in a dose-dependent manner when applied to 
primary cultured rat hepatocytes, [115] vascular smooth muscle cells, [116] murine 
macrophages, [117,118] and activated microglia. [114] In primary microglia culture,  the 
NO production can be suppressed to 50% and iNOS protein and mRNA expression can 
be downregulated to  70% by administration of DEX. [119] All the supportive evidences 
showed a well-established in vitro model for testing the DEX release from Ppy using our 
non-invasive EMF stimulator.   
 
4.1.2    Evidence of Neuronal Recovery by Inhibition of iNOS and ROS  
The enhanced production of ROS and NO has been reported to associate with neuronal 
death after SCI. Among the ROSs, H2O2 and OH. are known detrimental effectors for  
oxidative damage. Antioxidants and antioxidant enzyme can inhibit ROS and ameliorate 
motor neuron damage and  dysfunction after SCI. [120,121] The potential 
pathophysiological role of elevated iNOS level in SCI has been investigated in many 
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studies and many experimental models indicate that the inhibition of over-expressed 
iNOSs during earlier phase of SCI leads to a modest functional recovery. (See Table 4.1)  
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Table 4.1  iNOS inhibitors and their neuroprotective results. 
iNOS  inhibitor  Charateristics Results  Ref. 
Cyclosporin-A 
(CsA)  
Protect damage tissue from lipid peroxidation 
(initiated by free radicals) and reduce the 
formation of RNS, such as peroxynitrile. 
A significantly better myelination index, motor 





Nucleophilic hydrazine compound, selective 
inhibitor, more effective at inhibiting the 
enzymatic activity of iNOS than eNOS and 
nNOS.  
Decreased lesion volume and significant 
recovery of rat hindlimb motor function after 
spinal cord injury.   
[123] 
Flavokawain A  Significantly inhibited LPS-induced activation of  
JNK and p38 MAPK signaling pathway via NF-
jB and AP-1. 
Reduce iNOS expression and many pro-
inflammatory cytokines in macrophages, such 





Non-selective competitive inhibitor of NOS, 
associate to the L-Arg binding sites, usually as L-
Arg analogues. 
Results in reduction of  necrotic volume and 




Selective nNOS inhibitor and potent 
against iNOS 
Significantly decrease contusion volume after 




Oxidized the redox modulatory site of N-methyl-
D-aspartic acid  receptor. The production of NO 
complicate this receptor medicated neurotoxicity.  
Significantly decreased lesion size and increase 
axon density and promote the functional 
recovery of SCI.  
[127] 
NOS knock out 
mice  
iNOS gene deficient.  A gradual improvement of motor function and 
no observation of delayed neuron damage.   
[128] 
ASOs iNOS antisense oligonucleotides. Significantly decreased iNOS positive 
immunoreactive cells and  retard neuronal cell 






Selective iNOS inhibitor. As the results as ASOs treatment, but less 
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4.1.3    Gilal Cells in Spinal Cord Injury 
The spatial and temporal glial activation can further complicates and intensifies the 
detrimental effects after intial physical damadge at spinal cord, resulting in sequences 
sensory and motor repairment. Many previous studies reported a variety of astrocyte and 
microglial activation patterns in regards to different injury model, locations, and methods.  
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Table 4.2  Glial responses after SCI.  
Sites  Animal Injury Methods Glial Response After SCI Ref. 
Spinal Contusion Injury 
T10 Rat NYU-MASCIS Astrocytes: start day2 and decreased till day30 [133] 
T10 Rat IH Imapctor Glial:persistent activation for  2hrs- 3months [134] 
T12 Rat Metal Rod (2mm in diameter, weight 30g) Microglial:1-12wks [135] 
Spinal Cord Compression Injury 







Astrocytes: day2-1month  [138] 
Spinal Hemisection/Hemitransection Injury 
T13 Rat Adjustable wire knife, right lateral hemisection  
Astrocytes and microglial: day7 
persistent to 3months  [139] 
T12 Rat Micro-scissor, left lateral hemisection  
Microglial: start at day 1;      





Microglial: day2- over 3wks [141] 
Spinal Ishemic Injury 
T8 Rat 
Argon laser beam with 
560nm wavelengths 
after rose bengal 
injection 
Astrocytes and microglial: start at 
day2 [142] 
T8 Rat 
8kLux illumination with 
halogen lamp after rose 
bengal injection 
Astrocytes: <1hr-2wks [143] 
T8 Rabbit 
Argon laser beam with 
560nm wavelengths 
after rose bengal 
injection 
Astrocytes and microglial: start at 
2hrs [144] 
Spinal Excitotoxic Injury 





Quinolinic Acid          
(NMDA Receptor 
agonist) 
Astrocytes and microglial: start at 
day1 and developed from day 7 to 
1month 
[146] 
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4.1.4    In Vivo Applications  
In neuroscience study, various prosthetics and medical devices are commonly used to 
assist the patient with traumatic injury or other neurodegeneration diseases and 
neurologic disorder. Recording/stimulating electrode arrays often accompanied with 
these devices either to stimulate the neural connection and muscle movement or to 
analyze the encoded information from neuronal tissues. Because these devices can be 
invasive to the tissue and causes negative impacts on patients, the local delivery of anti-
inflammation drug could be an appropriate approach to optimize the conditions.  The 
local drug delivery generally can be used to achieve high concentration drug 
administration at targeted site while minimizing risk of side effects. Many studies have 
shown the anti-inflammation treatment of DEX in many implantation cases. DEX 
released from nitrocellulose-based coating materials on silicon neural probes can 
facilitate a long-term recording without accelerating the glial scar formation around the 
recording sites. [147] Other researches also have unveiled the potentials of DEX local 
delivery to eliminate the activation of microglia, macrophages (stained by ED-1), and 
CSPG expression (stained by CS56) one week after implantation.  In addition, the 
number and density of reactive astrocytes evidenced by glial fibrillary acidic protein 
(GFAP) staining were also remarkably reduced by DEX release at both 1 week and 4 
weeks after probes invasions to brain, indicating local treatment of DEX can reduce 
astroglial ovre-responses.[147]  
In addition to microglial and macrophages, astrocytes are indispensable component to 
modulate the inflammatory processes of neurological disease and neurotrauma. 
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Astrocytes produce many inflammatory chemokines, such as KC (also known as 
CXCL1), and MIP-2 (CCL2), immediately after injury and responsible for the early 
neuroinflammation.. The over-activation of astrocytes was also contribute to the 
inhibitory molecules, including of tenascin, semaphoring 3, ephrin-B2, slit proteins, and a 
CSPG after SCI. Especially for proteoglycans, it is believed that it creates the 
nonpermissive environment for axonal regeneration. Under the presence of these 
inhibitory molecules, the axons from peripheral regions are unable to reach to the damage 
site of spinal cord and end up to a dystrophic state causing the regeneration failures. [148] 
We can say,  the neuronal activity are mostly likely to be interrupted or inhibited not only 
by mechanical boundary but also by the production of inhibitory molecules induced from 
activatived astrocytes. [149,150] Manipulating the environment of the extracellular 
matrix and attenuating the production of inhibitory molecules would provide an 
opportunity for a successful neuronal recovery.  
Astrocytes reactivity and reactive astrogliosis were usually characterized as increases in 
GFAP level which occur rapidly after CNS injury, GFAP was generally considered as an 
indicator of alternations in astrocyte phenotype.  The severity of astrogliosis is classically 
determined based on the morphology, numbers, and levels of GFAP and vimentin 
expression. [151] Therefore, the massive up regulation of GFAP was associated with the 
increased spread of inflammation in response to all CNS injuries and disease. One 
previous study described that the proliferation of immunoreactive GFAP expressed 
reactive astrocytes increased as the motor neurons in lower spinal cord of mice 
progressively deteriorated. [152] Inhibition of over-activated GFAP postive astrocytes 
can promote white matter preservation and axonal sparing, allowing an improved 
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functional recovery after SCI.[153] The actual role of GFAP was also exploited along 
with astrocytes study in CNS. It is believed that GFAP, as intermediate filament in 
astrocytes, contributes to the maintenance of myelination and structuration of white 
matter,[154] but also glia scar formation with vimentin.  One study based on cultured 
neonatal astrocytes which are believed to have similar characteristics of reactive 
astrocytes unveiled that the inhibitory function of GFAP on neurite growth. The study 
using a GFAP null mice models response to direct injuries didn’t suggest the different 
degree of scar tissue formation or improved neuron production compared to wild type 
mice, but showed the poor scar formation in the case of neurotoxins application, 
infection, Alzheimer’s disease, and multiple sclerosis.[155]   
Since activation and reactive gliosis indicated by increased GFAP intermediate filament 
proteins proliferation, we used a GFAP-luc mice as animal model, which can express 
upregulated GFAP signals after SCI, to detect the release of DEX in vivo studies as well 
as its therapeutic effects for neuroinflammation treatment.  
 
4.2    Materials and Methods 
4.2.1    ROS Production in Challenged and Treated Microglial Cells. 
The microgilal BV-2 cells were mainteined in Dulbecco’s modified Eagle’s medium 
(Sigma-Aldrich) containing 10% fetal bovine serum, 100 IU/ml penicillin, and 100 μg/ml 
streptomycin at 37oC in a humidified incubator with 5% CO2. Cells were harvested by 
trypsinizing and reseeded in 12-well plate for 24 hours at cell density of 1*106. They 
were then incubated with 1μg/ml Lipopolysaccharides (LPS; Escherichia coli 026:B6 
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from Sigma-Aldrich) for 6 hours, and followed by 1μg/ml DEX treatment for 1 hour. In 
addition, approximately 30-40 mm2 size of PpyNWs-AuNps films were placed in cell 
culture and stimulated for 30 minutes or 1 hour by pulsed EMF after LPS challenge. The 
similar procedures were also applied to another group at exception of no stimulation of 
EMF. For control groups, cells were only received six hours of LPS challenge.  Then all 
cells were trypsinized, centrifuged, and resuspended in PBS containing 10μM oxidative 
stress indicator (CM-H2DCFDA, Molecular Probes). Suspended cells were then placed 
into the incubator for 1 hour, then the production level of ROS was detected using the 
fluorescence plate reader. ROS expression was also imaged by a fluorescence microscope 
with an X-Cite series 120PCQ fluorescence illumination source (Olympus IX 81 
inverted). Moreover, another strong oxidizing reagent, hydrogen peroxide (H2O2) was 
used to confirm the LPS results. The experiment was based on the company instruction 
for OxiSelect Intracellular ROS assay kit (Cell Biolabs, Inc.)  Briefly, BV-2 cells were 
seeded in black 96-well plates for 12 hours and then incubated with 1mM DCFH-DA 
solution for 1 hour. The medium with 20μM hydrogen peroxide was then placed in each 
wells except the ones for control groups and incubated for 30 minutes. DEX treatments 
were applied for another 15 minutes after disrecard hydrogen peroxide contained 
medium. To evaluate DEX release by EMF stimulation, the PpyNWs-AuNps films 
placed in the wells for a 15 minutes stimulation. The fluorescence signals of all samples 
was then read using a fluorescence plate reader. In all instances, the coil was placed 
below the culture plate during the EMF stimulation. 
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4.2.2    Immunofluorescence Labeling Assay. 
BV-2 cells were cultured on Poly-D-lysine (Sigma) pre-coated round cover glass (#1.5 
thickness, 12 mm) in 12-well plates for 24 hours. After appling LPS, DEX, and released 
DEX, BV-2 cells were fixed at room temperature for 30 minutes using 4% 
paraformaldehyde solution. Then, the cells were incubated in 1% albumin from bovine 
serum blocking buffer for 1 hour, and subsequently incubated in primary antibody 
solution containing anti-nitric oxide synthase II antibody (EMD Millipore) (1:400) 
overnight at 4 ℃. Next day, diluted Cy3 conjugated goat anti-rabbit IgG antibody 
solution (EMD Millipore) (1:100) were applied to cells for 2 hours. Dried cover glasses 
were mounted on glass slides using vectashield hardset mounting medium with DAPI 
(Vector Lab). These samples were all imaged with a confocal microscope (Leica SP5 
/STED /MP System). 
 
4.2.3    Surgical and Treatment Procedures 
The demonstration of surgical and treatment procedures are shown in Figure 4.3. All 
aspects of animal care and treatment were carried out according to the guidelines of 
Purdue Animal Care and Use Committee (PACUC). Female GFAP-luc transgenic mice 
were purchased from Taconic. Surgery began when mice reached the age 9-12 weeks old 
and their weight was above 22g. Animal anesthesia was applied by intraperitoneal 
injection with ketamine 90 mg/kg and xylazine 10 mg/kg.  All the mice then received a 
bilateral, hemilaminectomy procedure at low thoracic region. The dorsal surface of the 
dura mater was exposed at a size of approximately one third of the cord. SCI was induced 
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by clamping to exposed cord under stereoscopic illumination. For Ppy control and Ppy 
treatment group, the DEX doped polypyrrole films was lifted on a drop of sterile saline 
and deposited on the dorsal domain of injured spinal cord. The lesion was surgically 
closed in layers, and then skin were closed and sutured. Animals were then moved to 
their individual cage and warmed with incandescent lights until recovery. Also, all mice 
were received buprenorphine HCl after surgery and the next day.  
The control group only received the SCI. Sham-treated animals (Ppy control group) 
possessed DEX doped PpyNWs, though the polymer was not exposed to the EMF 
stimulation. For Ppy treatment groups, the first treatment of released DEX by EMF 
stimulation was conducted within three hours after surgery. During the treatment, the coil 
was positioned over the arch of the animal’s back and brought to the surface of the 
epicenter of spinal cord lesion site when animal were under isoflurane anesthesia. (See 
Figure 4.3) The highest intensity of the EMF was roughly at the center of coil. 
Stimulation of EMF was applied 2 hours daily  for seven days. The mice were euthanized 
and followed by fixation perfusion at seven days after injury. Two animals were 
euthanized before 7 days due to the condition of animals self-damaging their rear limbs, 
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4.2.4    Whole Animal Bioluminescent Imaging 
At day1, 3, and 7 after spinal cord injury, mice were imaged using Caliper IVIS Lumina 
II at the Purdue Multi-scale Imaging Center (MUSIC). One of common luciferase 
substrates, D-Luciferin - K+ Salt Bioluminescent Substrate (Perkin Elmer) at 15mg/ml in 
DPBS was freshly prepared and all mice received intraperitoneal injection at 10μl/g of 
body weight before imaging. All mice underwent imaging during short period of 
immobilization under isoflurane anesthesia.  Luciferin kinetic study was performed with 
peak wavelength at 560nm and the maximum signal was determined between 18-22 
minutes after luciferin injection. The quantitative data of luminescent density were 
confined at the region of interest (ROI) around spinal cord region and also analyzed with 
setting at the range of 9.5e5 to 1.2e7 p/sec/cm2/sr. A automatic ROI measurement 
methods is used to identify the bioluminescent emission automatically with fixed 
threshold.   
 
4.2.5    Statistical Analysis 
All the data are shown with standard error of the mean + SEM. Comparative independent 
student’s t test, Tukey's HSC multiple comparisons tests were used for in vitro studies,  
and one way ANOVA followed up with three Fisher's LSD post hoc were used for in 
vivo study to detect the statistical significance. Statistical significance were determined 
by a P-value < 0.05. Prior to conducting the ANOVA, the assumption of normality was 
evaluated and the normality test is determined based on the level of skew and kurtosis 
less than 2 and 9, respectively. 
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4. 3    Results 
4.3.1    ROS Detection 
ROS production was detected after challenge murine neonatal microglial cells (BV-2) 
with two toxins, LPS and H2O2. In one group, cells were received the LPS (Figure 4.1 A-
G) and in the other, the cells were directly insulted with H2O2 (Figure 4.1 H). 
Additionally, the treatment either by direct apply DEX or release DEX via EMF was also 









Figure 4.1  Composite fluorescence signals and quantitative measurement of ROS. (A) 
Control: without LPS insult. (B) BV-2 cells challenged by 1μg/ml LPS, showing intense 
ROS production indicated by green fluorescence signals. (C) Introduction of 1μg/ml 
DEX treatment after LPS insults (D) After LPS incubation, cells were applied with 
combination of DEX doped PpyNWs-AuNps film and EMF stimulation for 30 minutes 
(E) for 1 hour stimulation (F) without EMF stimulation. (G) Corresponding graph 
describes the quantitation of ROS production in panels (A-F). Values shown as percent 
normalized to control. (H) Quantitative data of ROS production after H2O2 insults and 
DEX treatment. * P < 0.05, ** P < 0.01. 
 
                                                                                                                                                                                                                                                              
82 
 
CM-H2DCFDA, as ROS indicator, was used to measure the ROS production during this 
experiment. BV-2 cells treated with LPS (1μg/ml) exhibited intense green fluorescence, 
indicating the enhanced production of oxidative stress (Figure 4.1 B). The addition of 
DEX (1μg/ml) after LPS challenge effectively suppressed ROS production during the 
inflammatory cascade (Figure 4.1 C). ROS production was nearly undetectable when 
applied DEX-doped PpyNWs-AuNps platform with EMF stimulation for 1 hour (Figure 
4.1 E). A less suppression of ROS activity occurred when shorter stimulation times 
(30mins) were applied (Figure 4.1 D). In contrast, DEX-doped PpyNWs-AuNps film not 
subjected to EMF stimulation did not show signs of ROS scavenging.  (Figure 4.1 F) 
Similarly, more ROS byproducts in BV-2 cells were observed after 20 μg/ml H2O2  
exposure. (Figure 4.1H). This increased level of ROS was supressed either by direct 
application of 10 μg/ml DEX for 15 mins or with 15 mins of EMF stimulation to the 
DEX coupled PpyNWs-AuNps.  
 
4.3.2     iNOS Suppression by Dexamethasone Release 
Above findings were further corroporated by the results of iNOS measurements. The 
iNOS expressions were demonstrated by labeling of Cy3 (red) fluorescence signal. The 
control group does not show any iNOS expression due to absence of LPS challenge. 
Microglial cells showed intense fluorescence signals (primarily localized in the 
cytoplasm regions) when exposed to a higher concentration of LPS (10μg/ml) (Figure 
4.2), showing significant upregulation of iNOS. A less upregulation of iNOS expression 
was observed at a reduced LPS concentration while PpyNWs-AuNps not stimulated with 
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EMF (Figure 4.2 DEX w/o STI) also showed a similar response. In both cases, there is 
apparent iNOS expression occurred, showing the potentials of NO-mediated cell 
damadge. In contrast, EMF stimulation of DEX conjugated PpyNWs-AuNps resulted in a 
strong suppression of iNOS as directly applied DEX treatment (Figure 4.2 DEX STI 1hr 
and DEX 1μg/ml), also indicating a reduced level of nitric oxide. These results addressed 
the successful DEX release using EMF stimulation and also indicated the stimulated 
DEX remain bioactivityfor iNOS supression.  These results are all in agreement with the 








Figure 4.2  Confocal images of the iNOS expression after LPS induction and DEX 
treatment in BV-2 cells. iNOS expression in BV-2 cells is shown as red fluorescence 
(CY3 column). Nuclear staining with DAPI is shown as blue signal (DAPI column). The 
control group didn't receive any LPS challenge and DEX treatment. The row LPS 
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10μg/ml indicate the stimulation of high concentration LPS and high iNOS production. 
Row LPS 1μg/ml showed lower concentration of LPS applied to the tested cell 
population. DEX doped PpyNWs-AuNps film not stimulated with EMF (DEX w/o STI) 
showed a similar response as in LPS 1μg/ml. Row LPS1μg/ml:DEX1μg/ml illustrates the 
results when direct DEX treatment applied while row LPS1μg/ml:DEX STI 1hr as 
comparison indicating the DEX relase treatment when PpyNWs-AuNps film was 
stimulated with EMF for 1 hour.   
 
4.3.3    Selection of Animal Injury Model 
GFAP – luc transgenic mice were chosen because they were genetically engineered to 
express firefly luciferase under the control of the GFAP promoter, so that they can 
express the level of GFAP protein as feature of astrocyte activation and reactive gliosis 
when there is alternation of astrocytes occurred in the healthy nerve tissue of CNS. This 
GFAP expression can be initiated by any insults, such as directly injury, bacterial 
infection, neurodegenerative disease, ischemic defects, and tumors. This technique 
combining transgenic mice with bioluminence imaging system can permit multi-
dimensional imaging of GFAP expression and its changing dynamics in the living 
animal.  
The SCI was induced at low thoracic regions with a compression method illustrated  in 
Figure 4.3. This is not a robusting injury and intentionally very mild to ensure the low 
mortality and not severe behavioral deficits during a week of study. The compression 
method has been reported to be able to active the astrocytes starting at day 1 after SCI. 
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[156,157] Since we focused on the study of neuroinflammation, not behavior testing, the 
compression method has been considered as suitable for this situation.   
 
Figure 4.3  Illustration of SCI procedures and EMF stimulation set-up. A) shows a spinal 
cord compression using blunted forceps. The dimensions are exaggerated for explanatory 
purposes. The cord was compressed to a depth of approximately 50 % of its diameter.  
The degree of lateral compression was also approximately >50% of the cord's diameter, 
and arrested by a detente built on the inner face of the forceps.  B)  The PpyNWs thin 
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film was physically placed on the injured site immediately after compression. C) 
Experimental setup.  This illustration shows the application of the EMF to a spinal cord 
injured mouse under anesthesia.  a) The background shows the integrated system and 
power supply for the generation of the EMF.  b) The coil positioned directly over the 
spinal cord injury in the mouse. 
 
4.3.4.  Neuroinflammation Attenuation by Drug Loaded Polypyrrole Implant 
All mice were distributed to three study groups: Control Group: animals only receive 
SCI; Ppy Control Group: animals received implantion of  DEX doped PpyNWs film, 
though they were not exposed to an externally stimulated electromagnetic field; Ppy 
Treatment Group (Experimental animals): the identical implantation procedures were 
applied as Ppy control group with exception to the EMF exposure. An applied EMF is 
required to induce the release of DEX from the PpyNWs. 
Figure 4.5 shown the bioluminescent images of three groups of GFAP-luc transgenic 
mice at day 1, 3 and 7 after SCI. The data illustrated by bioluminescent imaging system 
can provide the level and specific sites of GFAP expression and can compare relative 
GFAP intensity between groups.  The quantitative data can be expressed via converting 
the ROI of the images in relative lights units (CCD camera counts) to a physical units of 
radiance (photons/sec/cm2/sr). It means that the total flux of photons or radiance in each 
pixel (photons/sec) was integrated over the ROI area and then multiplied by one steradian 
(sr). The upregulation of GFAP mRNA or we may say luciferase protein after SCI can be 
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visualized after injection of the luciferase substrate D-luciferin due to the reaction shown 
as below Figure 4.4.  
 
Figure 4.4  Luciferin and luciferase reaction based bioluminesence imaging. 
The image and descriptive statistics of the GFAP expression are reported in Figure 4.5 
and 4.6. There was a trend for the intensity of GFAP to become reduced in all groups of 
animals. A statistical difference between two control groups during the entire experiment 
was not detected. There always had a clear and observable GFAP expression at every 
time point in these two control groups. It has also been shown that the EMF induced 
DEX release produced a relatively steep decline of GFAP level.. The experimental 
groups were always associated with numerically smallest mean level during the detection. 
At the first measurement day post-injury, the mean value of GFAP expression was 60% 
lower than control values, though this difference did not reach significance given the 
wide variability of the means 24 hours after surgical injury (P > 0.05). By day 3, this 
radical decline in experimental animals was very significant compare to the control 
groups both visually and statistically (P < 0.01). The statistical testing between control 
and Ppy treatment groups, between Ppy control and Ppy treatment groups also yielded a 
significant effect (P < 0.05) at day 7. Moreover, at post-surgery day 7, 2 of 5 
experimental animals did not possess a trace of GFAP. The other animals in this group at 
this time point revealed GFAP expression only at the barest level of detection. It has also 
been seen that the standard error of the means (SEM) of the experimental group was 
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significantly smaller compared to both control and Ppy control groups at day 3 and day 7. 
(See Figure 4.6) 
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Figure 4.5  Bioluminescent images of mice in control, Ppy control, and  Ppy treatment groups. Each row is one individual at 1 day, 
3 days, and 7 days post injury.  Note that, at day 7, the GFAP signal is at the barest level of detection or completely absent in 
treated animals. Clear GFAP signal from ear infections, as internal controls, are observed in all animals at all times. The 
luminescent intensity given in units of radiance is shown at the scale bar at the far right.  90 




Figure 4.6  Quantitative data of GFAP expression based on bioluminescent results. GFAP 
expression displayed is given as a function of time at post-injury.  Note that EMF - 
treated animals show striking and statistically significant reduced values compared to 
controls.  * P < 0.05; ** P < 0.01. 
GFAP signal associated with ear infections was also observed which was present with all 
received transgenic mice. (Figure 4.5) It is important to point out that GFAP positive ear 
infections in all animals can be provided as “Internal Control”. This Infection was not 
reduced or otherwise affected in either control groups or experimental samples. Note that 
the level of GFAP expression in ear regions (Figure 4.5) did not indicate the strongest 
signals when figure is captured since the kinetic study of this signal is based on the region 
of spinal cord. We suggest that the reduction of GFAP level in spinal cord region is 
explained by the likelihood of released DEX after EMF exposure. This observation 
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provides formal proof that the local release of DEX by smart PpyNWs was restricted to 
the spinal cord lesion, where DEX-doped PpyNWs were surgically placed and later 
exposed to an EMF. 
 
4.4    Discussion 
The functionality of glial cells was extensively investigated in SCI studies. Activated 
microglial cells triggers many pro-inflammatory factors, ROS, and RNS, initiating cell 
apoptosis cascades. Also, many studies implicate that not only physical barrier of 
astrocytes mediated scar formation, but also the inhibitory molecules triggered from 
reactive gliosis contributes to the abortive neuronal regeneration after SCI.  Thus, glial 
cells have been emerged as an attractive target in many CNS related pathological context.  
In this study, we used LPS and H2O2 challenged microglial cells (BV-2) in vitro and 
spinal cord compression model in vivo to simulate the neuroinflammation conditions and 
then detect the releasing profile of anti-inflammation drugs DEX using a novel 
application of EMF-sensitive conductive polymer based drug delivery systems under this 
neuroinflammation conditions.  
Among all the harmful molecules produced from gilal cells, we primarily study the ROS 
and RNS production. It has established that NO primarily produced from macrophages 
and microglial cells via iNOS expression and act as a neurotoxic agent in spinal cord 
injury model, brain ischemia, and hypoxia.  However, some researches also shown that 
NO may exerted neuroprotective functions and particularly resistant to neurodegeneration 
in Huntington’s disease. [158] Therefore, balancing the level of NO production is very 
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important and vary based on different neuronal degeneration disease and neurological 
deficits. According to many case studies of SCI, the reduction of NO-mediated 
neurotoxicity showed potentials to achieve the successful neuronal recovery and avoid 
the functional impairments.  
Since the possible ROS and NO reduction of DEX, we deliver the DEX from EMF 
sensitived conductive polymer Ppy to LPS and H2O2 challenged microglial cells, and test 
the successful delivery of DEX according to the cellular responses. The results showed 
dramatically suppression of iNOS expression by DEX at 1μg/ml and moderate reduction 
to ROS. Many studies also confirmed these outcomes. In the study of hyperglycemia, 
DEX has been proven to reduce ROS levels in multiple myeloma cells through regulation 
of thioredoxin activity.[159] Low concentrations of DEX in a range of 10nM to 1μM 
substantially inhibition of IL-1 beta, IL-6, and TNF-alpha secretion.[160,161] Lina Ruiz 
et al also reported that DEX can delay neutrophil apoptosis by inhibiting ROS generation. 
[162] In addition, DEX suppresses intracellular ROS production in platelets [163] and 
directly blocks LPS-induced ROS production in microglial cells by up regulation of 
MKP-1.[114] However, long term administration of DEX can accelerate the oxidation 
process in some tissues and imbalances the lipid metabolism. [164] One study has shown 
increased ROS levels of differentiated M2 macrophages induced by DEX when applying 
DEX for 7 days but not 2 days. [165] Our experiment also addressed similar 
phenomenon. DEX failed to reduce or , in some situation, initiated production of ROS 
when a higher concentration of DEX (10 μg/ml) was applied to a low concentration of 
LPS (1μg/ml) stimulated microglial cells.  Also, we challenge the cells with different 
concentration of H2O2 range from 5μM to100μM with various concentration of DEX at 
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similar range. The results showed that DEX can eliminate low production of ROS, but 
not for a high level of ROS. This is indicated by a failure ROS reduction of DEX when 
H2O2 at concentration of 50 μM or above were applied to the cells. (data not shown here) 
Although a clear explanation to the role of GFAP is still under exploration, it is important 
to realize that the GFAP level that not be expressed under normal circumstances indicate 
the changes in the function and secretion of the astrocytes and normally due to 
neuroinflammation related reative astrogliosis. Many investigations showed that 
increased oxidatively damaged proteins can also cause the increased GFAP expression in 
different neurodegeneration cases. [166,167,168]  In our SCI study,  a GFAP-luc 
transgenic mice combining with bioluminescent imaging technique were used to trace the 
spatial and temporal changes of GFAP expression after SCI. We reduced these GFAP 
signals by releasing DEX via EMF from local Ppy nanosouce which placed at spinal cord 
lesion. The results from our study indicated a significant statistical difference between 
treatment and control groups at day 3 and 7, but not the first day after injury although it 
showed an apparent numerically reduction of mean value in the treatment group. It 
propably due to the various responses of animals to traumatic injury in spinal cord and 
treatment. The selection of statistical testing methods is based on the assumption of 
normal distribution which determined depend on the skew and kurtosis value.  Mann-
Whitney testing as non-parametric test described a significant difference at day 1 (P < 
0.01).  Moreover, there is an obvious reducing tendency of GFAP expression at post-SCI 
in all three groups, but it quite different. 2 out of 5 control animals appeared GFAP 
signals at day 1, and decreased at Day 3, but prominent by Day 7, and other control 
animals showed a prominent GFAP expression from Day 1 up to Day 3, but vanished at 
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day 7. A similar GFAP expression and proliferation pattern after spinal cord compression 
injury has been reported using immunohistochemistry testing method. One reports 
indicated that the reactive astrocytes displaying GFAP signals by Day 1 and reach to the 
peak level at Day 3 post-SCI. [169] Other studies reported an increased GFAP level at the 
injured and its adjacent sites at day 1 after traumatic injury. It is then prodominent 
between 3 to 7 days and gradually decreased afterwards. [170] However, in the 
experimental groups, there was a consistent reduction in GFAP expression after initiation 
of SCI and showed similarity as described by Theriault et al. [169] 
It is also important to understand the plasicity of these astrocytes in CNS injury. There is 
no absolute detrimental role for them, they also can benefit to the injured tissues to 
certain level. For example, the proteoglycans produced by astrocytes may be protective 
for the surrounding viable tissues by limiting the proporgation of cavity after SCI. 
[171,172] It is beyond the scope of this report to critically review the biology of reative 
astrogliosis after SCI. Opinions vary significantly in many literatures on the role of 
reative astrocytes is detrimental or helpful to biological recovery functions.  We 
emphasize that there are more GFAP positive activated astrocytes accumulate at injury 
sites as their increased number of hypertrophy and largely increase the glioscars in open 
injury. These events are considered to be aspects of neuroinflammation in CNS injury. 
We can say with certainty that the corticosteroids drug DEX has performed anti-
inflammation properties which would be useful after SCI. These beneficial effects would 
be many and vary such as reduction of edema, lipid peroxidation, concomitant with cell 
survival.  Especially, the effects of DEX on astrocytes associated GFAP irradiation have 
been extensively reported in earlier papers. [147]  
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The glucocorticoid steroids drugs, such as methylprednisolone,  have been commonly 
used in clinical treatment of brain and spinal cord injury to inhibit post-traumatic lipid 
peroxidation and other physiological conditions in traumatic injury for more than 30 
years. A survey from USA indicated that corticosteroids are widely usded for 
management of traumatic head injury, taking for 64% of treatment centers. However, a 
randomized CRASH trail unveiled an increased risk of death under methylprednisolone 
treatment compare to the placebo groups. We need to emphasize that  corticosteroids, 
under debating, but still used in different condition of SCI. Unlike traumatic brain injury, 
there are many evidences support that corticosteroids treatment can results in beneficial 
outcomes, especially for motor functional recovery which proved in NASCIS-2 clinical 
trail. In addition, DEX administration to spinal cord injured cat had proved to have a 
remarkably functional recovery by eliminating the potassium loss. [178] This beneficial 
effect was considered to relate to the maintenance of cellular structural integrity offered 
by the steroid drugs. [179] Our studies also addressed the same results. A LDH (lactate 
dehydrogenase) assay, as the indicator of cell membrane integrity, was perform for DEX 
treatment to LPS challenged microglial cells. It showed a decreased level of LDH activity 
after DEX treatment, indicating the potential protection to cell membrane by DEX. (Data 
not shown here) However, some reports have shown that there is no statistical difference 
in the trauma score, average length of hospital stay, mortality, [173,174] and neurological 
benefit [175] between steroids treatment and without the treatment. 
It is noteworthy that the timing and dosages of corticosteroids drugs applied to the 
patients with acute spinal cord injury plays an key role and have been studied in many 
trials.  For example, "patient who receives methylprednisolone within 3 hours of injury 
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should be maintained on the treatment regimen for 24 hours. When methylprednisolone is 
initiated 3 to 8 hours after injury, patients should be maintained on steroid therapy for 48 
hours." [176] "Methylprednisolone sodium succinate (MPSS) has been shown to improve 
neurologic outcome and significant recovery in rodent motor function up to one year 
post-injury if administered within eight hours of injury and in a dose regimen of: bolus 
30mg/kg over 15 minutes, with maintenance infusion of 5.4 mg/kg per hour infused for 
23 hours." [177] Therefore, unsuccessful or even detrimental outcomes to patient with 
SCI could relate to the difference in administration. In our animal studies, we applied the 
treatment within 3 hours after SCI and locally administrate the drugs to injured region. It 
could result in a different theraupeutic effects compared to the traditional systemically 
drug delivery. 
Many clinical results showed improvment after SCI by modulating inflammatory 
processes, but the steroid treatment alone is not sufficient enough to get fully recovery for 
patient with SCI. A combination approaches, often together with pharmacological 
therapeutics and some of non-pharmacological strategies, such as targeted rehabilitation, 
individually designed cognitive training and exercise, or multisensory stimulation , could 
be a more beneficial therapeutics intervention to the patient with SCI.   
According to our study, a local steroids treatment might have different impacts for CNS 
treatment compare to the systematic administration which applied to all earlier studies. 
The targeting strategies of drug release can simply accomplished by physical placement 
by coating the drug loaded materials with implants, and not encumbered by side effects. 
Our technique also can be as simple as placement using a biopsy needle. Moreover, 
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despite the treatment of corticosteroids drugs DEX are less capable to suppress lipid 
peroxidation compared to MPSS in spinal cord studies  and steroid treatment alone has its 
limitation in spinal cord injury, this Ppy mediated drug delivery strategies are not limited 
only for the treatment of SCI. It can broaden the potential application for local treatment 
to different diseases, such as rheumatic disorders, decubitus ulcerations, and even early 
tumor formations in breast, lung, prostrate.  Additionally,  this drug delivery system has 
been proved that it can successfully conjugated different molecules, such as NT-3, NGF, 
BDGF, ATP etc, such that it can be used in various applications. Especially, the 
administration of the drugs can be controlled by external stimulation of electromagnetic 
field without any physical invasive contact to human tissues.  This drug delivery system 
opens the door to many known therapies that cannot be easily or safely applied 
systemically, but till now, could not be delivered continuously for many days to specific 








SYNTHESIS AND CHARACTERISTICS OF  
SIRNAS CONJUGATED CHITOSAN NANOPARTICLES 
 
5.1    Introduction 
5.1.1    Evolution of Post-transcriptional Gene Silencing. 
In 1990, the first study of post-transcriptional gene silencing was investigated  regarding 
to the promoter in the gene controlling the color of Petunia flowers. In 1998, Andrew Z. 
Fire and Craig C. Mello, who later on were awarded the Nobel Prize in Physiology or 
Medicine 2006, discovered a sufficient gene activity silencing by introducing the double-
stranded RNA into animal cells. This discovery of RNA interference introduced a 
powerful biological and therapeutic tool in medicine. Meanwhile, Alnylam 
Pharmaceuticals (which mainly focuses on the development of RNA interference (RNAi) 
based gene therapeutics) first reported data for use of RNAi therapeutics in rodent in 
2004 and in primates in 2006. In 2008,  RNAi was shown as the potential therapeutics for 
the use in human.  
The strategies of this post-transcriptional silencing of gene expression was rapidly 
developed in only a decade, but has proven its strong and effective therapeutic effects on 
genetically oriented disease.  Reduction in targeted messenger RNA levels and their 
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associated gene activity can be initiated by either microRNA (miRNAs), short hairpin 
RNA(shRNAs), synthetic short interfering RNA (siRNAs), or even single-stranded 
antisense oligonucleotides (ODNs) and ribozymes. The differences of these mRNA 
antisense approaches can result in a very different level of cellular uptake, transfection 
efficiency, and toxicity.  Their characteristics can also lead to different procedures for 
mRNA inhibition. MicroRNAs are considered as an artificial miRNAs and mimics the 
primary miRNA stem-loops, shRNAs are processed pre-miRNAs and transcribed as 
sense and antisense sequences connected by a loop of unpaired nucleotides. In contrast, 
siRNA is a laboratory-made synthetic miRNAs and can be engineered to be perfectly 
complementary to targeted sequences. In this endogenous pathway, the effects of both 
microRNAs and shRNAs are initiated at the nucleus, Drosha-DGCR8 process primary 
miRNAs to pre-miRNAs and followed by the cytoplasm transportation of Exportin-5. 
The cleaving of Dicer removes loop region and produces the desired mature miRNAs as 
single strand RNAs.  RNA induced silencing complex (RISC) along with this single 
strand RNAs reach to the targeted specific sequences for silencing and eventually leads to 
the knockdown of this protein expression. Synthesized siRNAs can be directly 
transfected into cytoplasm, follow by either directly loaded onto RISC or untilize a Dicer 
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5.1.2    Pros and Cons of SiRNAs Therapeutic Strategies 
The success of RNAi based strategies has led to many ongoing clinical trials and 
developmental pipelines. Of them, siRNAs are shown promising outcomes due to 
efficient gene silencing and highly specific inhibition of the target of the interest. Another 
key feature is that, unlike microRNAs and shRNAs, the process of siRNAs occurs inside 
the cytoplasm instead of the nucleus, therefore it limits the risks of unexpected genome 
modification. Since shRNAs are endogenously produced, they have  long lasting gene-
silencing effects whereas the synthetic siRNAs only have short inhibitory effects 
(generally last for 3-5 days) because of their constant cell division as well as  intracellular 
degradation. But siRNAs were proven relatively more stable in the bloodstream 
compared to ODNs and ribozymes which only remain stable for up to a few minutes, 
even though ODNs and ribozymes more easily pass through cell membrane due to less 
negative charges on them compared to siRNAs.  The long duration of inhibitory effects 
can be used in the condition with highly expressed mRNA levels but could be 
detrimental. For example, it can induce inappropriate immune response and interference 
with the endogenous miRNA pathways - both can eventually lead to toxic effects.  
From a pharmaceutical industrial perspectives, the low cost and easy synthesis of siRNAs 
does not need to involve either cellular systems or complicated protein purification 
procedures, suggesting the promising advantages over other small molecule drugs.  
Moreover, siRNAs have relatively low toxicity compared to organically synthesized 
drugs due to their natural nucleotide components. Therefore, siRNAs have promising 
potential in treatment of various gene oriented diseases. However, there are many 
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remaining challenges ahead and could affect possible clinical application. The primary 
biological challenges of siRNAs are described below. [180]  
1) Off target effects.  The major reasons are due to 3′ UTR or its homologous 
sequences are present in siRNAs.  
2) Non-specific immune response. Certain siRNAs sequences with 5′-UGUGU-3′ or 
5′-GUCCUUCAA-3′ motifs have the potential to initiate the inappropriate 
activation of immune systems by producing interferon and interleukin products. 
Many researchers have also indicated that the siRNAs with long nucleotides 
(>30bp) or at a high concentrations could also cause interferon or interleukin 
responses in certain cell lines by reticuloendothelial system (RES). 
3) Saturating the RISC. Due to the protein silencing mechanism of siRNA, excessive 
amounts of siRNAs might influence the normal activity of cellular miRNA.  
4) Low transfection efficiency/ poor cell penetration. siRNAs are unable to passively 
diffuse through negatively charged cellular membranes due to their anionic charge 
and consequent electrostatic repulsion between them. [181] 
5)  Poor cellular uptake.  Apart from the reason of inability of siRNAs crossing 
anionic cell membrane, rapid degradation of siRNAs by nucleases also can limit 
the cellular uptake. SiRNAs especially through systematic administration into 
bloodstream can easily undergo a degradation caused by relative larger amount of 
ribonucleases (RNAses) in the blood, aggregation with serum proteins, or limited 
blood stability. The lack of a specific delivery system to the target during siRNA 
delivery is also a particular limitation for siRNAs therapeutic strategies.    
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6) Lysosomal compartmentalization. Endocytic vesicle can entrapped the siRNAs in 
lysosomes which prevents the efficient release siRNA into the cytoplasm.   
7) Rapid renal excretion. This is mainly due to the capture of mononuclear 
phagocytic cells which leads to a rapid clearance from the circulation.    
 
5.1.3    SiRNAs Inhibition in Spinal Cord Trauma 
The exploration of siRNA strategies in central nerve system disease are ongoing and 
involved in an broad applications from neurodegenration, cancer glioma, pain syndromes, 
to primary and secondary damages. In the case of SCI, various target proteins were 
investigated to inhibit using siRNAs strategies. Alnylam/Merck collaboration focused on 
the development of RNAi therapeutics targeted to Nogo pathway for SCI treatment. 
Since Nogo receptor is important axonal inhibitor, inhibiting its associated pathway could 
potentially improve neuronal outgrowth and injury conditions, many other research 
groups dedicated to the study on the downstream of signaling pathway, such as RhoA and 
ROCK signaling pathways. [182]  Although RhoA specific siRNA treatment did not 
indicate the recovery of motor function, but controlled tactile hypersensitivity and 
significant improved white matter and serotonergic axonal regrowth. Also, the 
accumulation of ED1+macrophages is dramatically reduced which limits imflammation. 
[183] Pretreatment of ERK2 siRNAs has been reported to improve locomoter 
performance, so does ephrinB3 siRNA inhibitory strategies which are based on reversal 
signaling of ephrinB3 promote axonal pruning and regeneration as well as synapse 
formation. [184]  
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Other findings also focus on the reduction of scar tissue formation after injury in order to 
reconstruct neuronal growth conditions by delivering siRNAs to the injured sites. For 
example, GFAP siRNAs combined with photomechanical wave-driven approach shown a 
significant locomotive improvement after SCI.[185] SiRNA targeting to telomerase 
reverse transcriptase (TERT) and CSPG were also developed to control astroglial scar 
formation and to promote robust axonal regeneration. [186,187] In addition, matrix 
metalloproteinase-3 (MMP-3) siRNAs can prevent the increased permeability and 
disruption of blood-spinal cord barrier after SCI and lead to the potential for functional 
recovery.[188]  
Other siRNA applications have been used in other CNS diseases such as stroke or 
neurodegneration disease and could be potentially used for SCI treatment. The siRNAs 
targeting apoptosis mediated protein, such as CCAAT-enhancer-binding protein 
homologous protein (CHOP) and caspase 3, might be used to control cell death after SCI.   
Our study focused on the targeting to the macrophage and its initiated pro-inflammatory 
molecules which plays a key role in secondary injury after SCI. The hallmark expression 
of detrimental macrophages is iNOS expression. Therefore, siRNAs targeting of iNOS as 
a treatment strategy was hypothesized to be able to alleviate NO production and improve 
injured conditions of spinal cords. More details will be addressed in chapter 6.  
 
5.1.4   SiRNAs Delivery Strategies  
The remaining challenges described in chapter 5.1.3 result in a large scale of 
development of siRNAs based delivery materials and chemical modifications. Many 
studies have proved that these modulations can solve the existing limitation of siRNAs 
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and optimize the outcomes of this siRNAs application. Generally, the delivery strategies 
usually involved viral vectors and non-viral vectors materials. Despite the viral vectors 
based delivery system shown the successful results of gene silencing, the danger of viral 
toxicity and relatively strong immune responses from the host still present. Many studies 
have indicated the possibility of unexpected inflammatory immune reactions, insertional 
mutagenesis, oversaturation of RNAi pathways, and cellular toxicity that were caused by 
viral vectors carried siRNAs delivery. These obstacles directed many researchers to 
pursue safe carriers for siRNA therapeutics.  Complexes of siRNAs with various 
materials, such as polymers, lipids, peptides, antibodies, aptamers and small molecules, 
as non-viral vector carriers, have been extensively developed. They have been considered 
to be able to protect the siRNA from the RNase-rich in vivo environment and deliver 
them to the targeted cells and tissues, showing more efficient silencing outcomes 
compare to siRNAs alone.  
Over many recorded RNAi based clinical trials and commercial products, lipid 
nanoparticles or lipid based transfection reagents have been widely used to assist the 
siRNAs crossing the cell membrane. However, they have also been reported to be 
responsible for cytotoxicity. According to earlier and current studies, the assisted delivery 
of siRNAs favors the cationic polymer because siRNAs are anionic. Therefore positive 
charged polymers was vulnerable to synthesis with negative charged phosphate group of 
siRNAs. This self-assembly formation of inter-polyelectrolyte complexes with drugs is a 
non-covalent electrostatic complex formation, which is a very simple and reliable 
approach. Meanwhile, the cationic polymer shares a similar feature as a lipid based 
material and can easily carry siRNAs crossing cellular membranes.  
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Chitosan, as a linear binary polysaccharide, comprised of beta linked 2-amino-2deoxy-
beta-D-gluocose(GlcN; D-unit) and N-acetylated analogue (Glc NAc; A-unit). It can be 
protonated in slightly acidic conditions, expressing the cationic polymers nature. 
Chitosan also can process the properties of low costs as well as biocompatible and 
biodegradable which can minimize the side effects and the possible cytotoxicity. It is 
currently used as a common dietary supplement and has been classified as generally 
recognized as safe (GRAS) by the FDA. It is considered to be a promising carrier for the 
delivery of siRNAs and has been extensively investigated. Moreover, a relatively short 
transfection time of siRNAs (approximately 4 hours) when assisted with chitosan Nps 
also provides the possibility in clinical applications.[189]  
Many previous findings exploited siRNAs conjugated chitosan Nps were successfully 
used in various disease and medical conditions, but mainly focus on the anti-tumor 
effects. Some reports have indicated that the mucoadhesive and permeation features of 
chitosan can be used to delivery siRNAs to the respiratory sites by intranasal 
administration or drop wise into the trachea to treat pulmonary cancer. [189,190] The 
chitosan mediated siRNAs deliverery was also widely developed for other cancer cell 
lines, such as hepatocellular carcinoma, [191] colorectal cancer cells, [192] cervix, ovary, 
mammary carcinoma, [193,194] and leukemia. [195] A novel strategy using chitosan Nps 
to deliver siRNAs to peritoneal macrophages to reduce inflammation in an arthritis model 
has also been reported.[196] However, in central nervous system study, the chitosan 
mediated siRNAs strategies is still underdeveloped. P-glycoprotein siRNAs conjugated 
chitosan complexes were tested to be efficient to penetrate blood-brain barrier by 
silencing the efflux pumps P-glycoprotein which involved the maintenance of brain 
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barriers.[197] Efficient neurite growth and spinal cord repair has also been reported by 
deliverying of Rho siRNAs via chitosan Nps. [198] Most importantly, chitosan can limit 
lipid peroxidation and propagated damag at cell membranes in order to  prevent 
secondary injury after SCI. [199]  
Therefore, chitosan can be developed as a good candidate for siRNA carriers base on the 
nature of the materials and the various supportive and successful studies.   
 
5.1.5    Types and Modification of Chitosan for SiRNAs Delivery  
The most important characteristic of chitosan is that it can offer a variety of modification 
according to the requirement  of different applications.  The modifications of chitosan can 
improve siRNAs delivery by enhancing administration efficiency.  Trimethyl chitosan 
with cysteine conjugate has shown an enhanced mucoadhesion and permeation, therefore, 
it can be successfully used in nasal administration.[200] Encapsulation of (+)-catechin 
(C) and (-)-epigallocatechin gallate (EGCg) or crosslinking with hydroxypropyl 
methykellulose phthalate (HPMCP) with chitosan Nps has also been proved to increase 
the intestinal adhesion, penetration and absorption in order to optimize oral 
administrations. Although N-octyl-O- glycol modification of chitosan Nps did not show 
significant improvement during intravenous administration, it has been reported to have 
good biocompatability without signs of cytotoxicity. [201]  
Additionally, modified chitosans were especially helpful for transfection efficiency in 
siRNAs delivery.  Gaspar et al. synthesized chitosan- histidine-arginine (CH-H-R) based 
Nps for plasmid DNA delivery. These demonstratd remarkably higher transfection 
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efficiency than unmodified chitosan and without leading to any cytotoxic effect. [202] 
The design of trimethylchitosan/siRNA complexes is through quaternization of amine 
groups to creat the enhanced protonization of chitosan and help its interaction with 
siRNAs. [203] Chitosan grafted with PEI have increased long-term transfection 
efficiency and decreased cytotoxicity than PEI alone. Furthermore, the proton-buffering 
ability of PEI can catalyze the osmolysis of endosomes and help siRNA nanocomplexes 
easier escape into the cytosol than chitosan alone. [201] The optimization of transfection 
efficiency can be further supported by the good stability of siRNA conjugated chitosan 
Nps. Ionic crosslink sodium tripolyphosphate(TPP) with chitosan Nps suggest a new 
strategy to protect the siRNAs in serum contained conditions and shows a more strong 
stability with siRNAs. [204] Deoxycholic acid incorporated with chitosan showed good 
stability during the delivery process due to hydrophobic property of deoxycholic acids. 
[205] At last, from clinical application perspectives, the conjugation of PEG on chitosan-
siRNAs Nps allowed lyophilization for a longer shelf life and avoid aggregation during 
systematic delivery. [206]  In summary, the selection of nanocarriers for siRNAs highly 
relies on the characteristics of materials and its targeted cells and tissues. Different 
modification or copolymerization approaches allow chitosan processing much broader 
applications. 
Intriguingly, recent work raises promising results of enhanced transfection efficiency and 
alleviated side effects when using ligand mediated targeting methods. [207] Our studies 
focused on this modification of chitosan with ligand conjugation to achieve specific cell 
targeting and improve therapeutic outcomes. Various chitosan salts, such as chitosan 
glutamate (CS-Glu) and chitosan hydrochloride (CS-HCl),  are also developed for in vitro 
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siRNA delivery, because of their high solubility at physiological pH.  The different types 
of chitosan salts have much less influence on transfection efficiency of functionally 
active siRNA in comparison to the molecular weight of chitosan salts and weight ratio or 
N/P ratio between siRNAs and chitosans. [208] Chitosan hydrochloride is readily soluble 
in water, and its properties as a siRNA carrier was also investigated in our experiment for 
conjugating different targeting motifs.     
 
5.2    Material and Methods 
5.2.1    Synthesis of SiRNAs Conjugated Chitosan Nanoparticles 
Four different Chitosan/siRNA Nps were prepared, three of them conjugated with 
targeting ligands.  Low molecular weight chitosan was purchased from sigma and 
dissolved in 0.2 M sodium acetate buffer (pH 4.5), and the solution was adjusted to 
pH5.5. (indicated as Chi) For antibody conjugated siRNA/chitosan, Purified mouse IgG 
solution was mixed with chitosan solution which dissolved in 0.2 M sodium acetate 
buffer at a molar ratio of 1:1 and final concentration of chitosan at 200μg/ml. The 
crosslinking agents of 0.2 mM 1-Ethyl-3-[3- dimethylaminopropyl]carbodiimide 
hydrochloride (EDC) and 0.5 mM N-hydroxysulfosuccinimide (sulfo-NHS) were added 
to the mixture, and then stirred for 24 h at 4°C.  The next day, the solution were injected 
into 10K MWCO slide-A-Lyzer Dialysis Cassettes (Pierce) to remove uninterested 
molecules based on the instruction from company for 48 hours. (indicated as Ab-Chi). A 
second strategy of Ab conjugation with chitosan Nps is also performed and the water 
soluble crosslinking agent Bis[sulfosuccinimidyl] suberate (BS3) were used.  A 30 fold 
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molar excess of the crosslinker BS3 solution compare to the protein was added to the 
sample solutions which containing a morlar ratio 1:1 of IgG solution and chitosan 
solution which at final concentration of 200μg/ml. In this case, water soluable chitosan 
hydrochloride were used (Novamatrix, Protasan up CL114).  This reaction mixture were 
then incubated for 30 mins at room temperature and then followed by 7K MWCO zeta 
spin desalting columns (Pierce) (indicated as Ab-WSC). Before synthesis of 
siRNA/chitosan Nps, different ratio of prepared IgG conjugated chitosan solution (10%, 
20%, and 30%) were mixed with either 200μg/ml chitosan solution dissolved in 0.2 M 
sodium acetate buffer or 200μg/ml water soluble chitosans. Also, Mannosylated-chitosan 
solution were also prepared before synthesis with siRNA. This synthesis procedure was 
reported in Tae Hee Kim et al. [209] Briefly, mannopyranosylphenylisothiocyanate 
(Sigma-Aldrich) was dissolved in 1ml DMSO and then added to 60mg Chitosan 
(Novamatrix,  Protasan up CL114) in 1ml miliQ water, and the solution was stirred for 24 
hours at room temperature. Isopropanol solution was added to chitosan solution to 
precipitate the mannosylated-chitosan and followed by repeated centrifugation and wash. 
The collected precipitations were dried in high vacuum, and concentration of 200μg/ml 
mannosylated-chitosan was prepared before siRNA synthesis (indicated as M-WSC). 
Concentration of different chitosan solution at 200μg/ml was seperately prepared and 
20μl of 20μM iNOS-siRNAs were added to 1ml chitosan solution while stirring and 
remain at room temperature for 1 hour. 
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5.2.2    Transmission Electron Microscopy 
All samples were imaged using a FEI Tecnai T20 transmission electron microscope 
operated at 200kV. One drop of chitosan Nps dispersed solution deposited onto a mesh 
copper grid coated with amorphous carbon and allowed to settle at room temperature for 
2 mins. Negative staining was subsequently performed by swishing through 2% uranyl 
acetate droplet before imaging.  
 
5.2.3    Size and Surface Charge of Nanoparticles 
The size and zeta potential of the nanoparticles was analyzed using Zetasizer Nano ZS. 
Both size and zeta potential were measured in triplicate. Measurements were set at 173 
degree and a temperature of 25 degree. The sample solution was placed in disposable 
cuvettes or zeta potential capillary cells respectively for size or zeta potential 
measurements.  The z-average hydrodynamic diameter indicated size of the nanoparticles 
and calculated based on the viscosity and refractive index of water. The zeta potential 
was quantified based on the principle of phase analysis light scattering.  
 
5.2.4    Gel Retardation Assay 
Poly(l-aspartic acid) (PAA) displacement assay was conducted to detect the integrity of 
siRNA conjugated chitosan Nps. Polyanion PAA (Santa Cruz Biotechnology) were used 
to displac negatively charged siRNA from positively charged chitosan. Nanoparticles 
were incubated with or without PAA at concentration of 5mg/ml.  A1 to 4 volumetric 
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ratio between PAA and nanocomplexes was used, and then they were incubated at 37 oC 
for 30mins. 50ul of sample solutions containing 0.532μg of siRNAs were placed into 
each wells of 10% Mini-PROTEIN TBE poly-acrylamide gels. Electrophoresis was then 
performed at 100V for approximatly100 mins. The gel was then transferred to SYBR 
gold nucleic acid staining solution for 30 mins and visualized using GBox imager. 
 
5.2.5    Toxicity Studies 
Toxicity of siRNAs and different designed Chitosan Nps in macrophages cultures were 
detected based on the morphology of the murine bone marrow-derived macrophages 
(BMDM). Macrophages were cultured in 24-wells plate and maintained as described in 
6.2.1 setion. They were incubated at both high concentration (5μl of 20μM siRNA with 
6.5μl of Lipofectamine 2000 per well) and low concentration (2μl of 20μM siRNA with 
2.5μl of Lipofectamine 2000 per well) of siRNAs and siRNAs without transfection 
reagent, as well as different chitosan Nps for 4 hours. Macrophages were observed and 
imaged using Olympus IX 81 inverted microscope.  
 
5.3    Results 
5.3.1    Chitosan Nanoparticles Morphology 
To optimize siRNAs conjugated chitosan Nps, the molecular weight (MW), degree of 
deacetylation (DD), pH, and N/P ratio (or weight ratio) as important criteria were 
considered in the design of nanoparticles formation.  Many successful siRNA conjugated 
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chitosan Nps have shown that chitosan with MW at range of 60 to 170kDa and higher 
DD value between 75%-90% would produce the Nps with reasonable size and surface 
charge. It also remains the stability of siRNAs during the distribution in bio-environment 
and allows the up-taking of different cell types without rapid degradation.  In our 
experiment, all four chitosan nanocomplexes were formed using chitosan at the range 
mentioned above. Additionally, an weight  ratio approximately at 37.5 was also 
predetermined according to earlier publications and used in our study. [210] The 
morphologies of four different chitosan Nps are illustrated in Figure 5.1.  Both 
Chi/siRNAs Nps and M-WSC/siRNAs Nps showed a smooth surface of nanocomplexes 
with spherical-like shapes. In the case of two Ab conjugated chitosan Nps, the Nps 
predominantly exhibited a less smooth surface.  
 
 




Figure 5.1  Transmission electron microscopy images of different siRNAs conjugated 
chitosan Nanoparticles. The scale bar for Chi/siRNA Nps and  M-WSC/siRNA Nps is 
0.5μm, and for Ab-Chi/siRNA Nps and Ab-WSC/siRNA Nps is 0.2μm.    
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5.3.2    Particle Size and Surface Charge 
Size distribution and surface charge analysis was performed by DLS and shown in Table 
5.1. Mean particle size of Chi/siRNAs Nps were measured as 272.2+/- 8.13 nm, and 
266.57+/-8.66 nm for M-WSC/siRNAs. The size of Ab conjugated chitosan Nps with 
different Ab ratio were also tested and showed that 10% Ab-Chi/siRNAs Nps have an 
average hydrodynamic diameter 295.53+/-6.47nm, 350.58+/-9.63nm for 20% Ab-
Chi/siRNAs Nps, and 385.73+/-4.78nm for 30% Ab-Chi/siRNAs Nps. A slightly 
increased particle size was observed. A much larger size of Ab-WSC/siRNA Nps was 
detected when using BS3 conjugation methods to link Ab with chitosan. Different Ab 
ratios have also been performed and showed similar particle size, only 20% Ab displayed 
here corresponding to later study results. Three nanoparticles (Chi/siRNAs Nps, M-
WSC/siRNAs Nps, Ab-Chi/siRNAs) have slightly different particle size, but no 
detectable statistical difference. In addition, TEM images (Figure 5.1) shown the various 
sizes of chitosan Nps, the smaller particle size was considered due to the lower molecular 
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Table 5.1  Size distribution and surface charge of different siRNAs conjugated chitosan 
Nps.  
Name  Size (nm) Zeta potential ζ(mV) 
Chi/siRNA Nps 272.2+/- 8.13 23.63+/-0.18 
M-WSC/siRNA Nps 266.57+/-8.66 35.13+/-2.19 
10% Ab-Chi/siRNA Nps 295.53+/-6.47 24.33+/-0.73 
20% Ab-Chi/siRNA Nps 350.58+/-9.63 21.93+/-0.61 
30% Ab-Chi/siRNA Nps 385.73+/-4.78 17.77+/-0.18 
20% Ab-WSC/siRNA Nps 580.73+/-18.37 11.27+/-0.81 
 
During our studies, zeta potential analysis suggested that all nanocomplexes were 
positively charged. M-WSC/siRNA Nps have a higher zeta potentials than other siRNA 
loaded chitosan Nps, showing these Nps were more stable in suspension. In contrast, 20% 
Ab-WSC/siRNA Nps had a very low zeta potential approximately at 11.27+/-0.81mv. 
The synthesis procedures and/or instinct properties of these Nps needs further 
optimization and investigation.  Other chitosan Nps possess an approximately 25mV zeta 
potentials.  They are at a good stability conditions. Moreover, low zeta potential in Ab-
Chi/siRNA Nps with higher Ab ratio were also observed, indicating the poor stability of 
30% Ab-Chi/siRNA Nps compared to 10% Ab-Chi/siRNA Nps.      
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5.3.3    Binding Affinity Between SiRNAs and Chitosan Nanoparticles 
Electrophoretic mobility tests were performed to evaluate the chitosan and siRNA 
complexion efficiencies. siRNA must be stable in a bio-environment and can avoid 
digestion or degradation by various nucleases in order to have maximal activity for 
specific gene knockdown. The negatively charged siRNAs was synthesized with chitosan 
and formed nanoparticles to protect the siRNAs from degration. Therefore, they would 
not easily separate from the nanoparticles and migrated down during electrophoresis. Co-
administration of polyanions PAA can be used as a competitor to displace the siRNA 
from chitosan nanocomplexes. According to our results in Figure 5.2, the free siRNAs 
without chitosan Nps protection migrated down and showed detectable bands. Moreover, 
in all three chitosan nanocomplexes, the addition of PAA also results in the moving of 
siRNAs, and the bands showed in the figure indicated that siRNAs were displaced and 
move out the particle complexes as free siRNAs condition. All three chitosan 
nanocomplexes without incubation of PAA show any sign of siRNAs bands and 
demonstrating the fully protection of chitosan Nps to siRNAs and their stability.  
 




Figure 5.2  Gel retardation assay indicating the integrity of chitosan nanoparticles.  
 
5.3.4    Low Cytotoxicity of Chitosan Nanoparticles 
After 4 hours incubation at high concentration and low concentration of siRNAs and 
different chitosan Nps, murine bone-marrow derivatived macrophages expressed 
different morphology. The healthy status of macrophages without any treatment were 
also inspected. There is obvious sign of detachment of the cells and dramatically decrease 
of cell amount after high concentration of siRNAs incubation.  For low concentration of 
siRNAs treatment, some of cell cytoplasmic vacuolation and granularity were observed.  
It is due to the slight toxin appeared in the present of lipid based reagents in the serum 
contained medium during transfection. In the contrast, there is no sign of deterioration of 
cells without transfection reagents. Very few granularities in the medium were also found 
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in three  different chitosan nanopartilces, but majority of the cells remain their shape and 
appearance.    
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Figure 5.3  Morphology images of macrophages after treatment of siRNAs (at both high and low concentration) and different 
siRNA conjugated chitosan Nanoparticles (including Chi/siRNA Nps, M-WSC/siRNA Nps, and Ab-Chi/siRNA Nps). 120 
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5.4    Discussion 
Due to the diverse nature of disease targets and bio-environments for siRNA gene 
silencing, there is no single ideal nanocarrier that is universally applicable. In our study, 
we tested the condition of SCI and developed a ligand conjugated natural polymer 
mediated siRNA delivery system to reduce inflammation induced sendary injury and 
promote the recovery of neural cells and tissues after SCI. We are searching for an 
optimal delivery tool that can be systematically administered safely and repeatable to the 
animal, and can deliver the siRNA specifically and efficiently to the targeted site. Unlike 
M2 anti-inflammation macrophages, M1 macrophages are pro-inflammation, and it can 
produce many pro-inflammatory molecules, especially a high level of NO production 
which subsequently result in the cellular death and tissue damadge at spinal cord. Thus, 
these M1 macrophages were considered as our cellular targets in this study. Since the 
surface marker expressed differently in pro- and anti - inflammation macrophages after 
SCI, we exploited an antibody strategy to target specific macrophages in order to enhance 
the theraupeutic outcomes.   
Natural polymer chitosan was used in this study especially due to its biocompatibility, 
less cytotoxicity as well as convenient and reproducible synthesis procedures with 
siRNAs. Many publications have shown its safe and successful outcomes when 
delivering siRNAs. Our data has shown some observed toxic events when apply siRNA 
with lipid based transfection agents, but rarely detected in the cells with chitosan Np 
application.  
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Most importantly, the various possibility of chitosan modification and conjugation can 
avoid the intrinsic limitations of this polymer and improve its potential applications. We 
first focused on conjugating antibodies with chitosan polymers for targeting and 
considered two possible IgG incorporation methods in both acidic and neutral conditions.   
One approach is using combination of EDC and sulfo-NHS to react the carboxyl group of 
antibody with amine group of chitosan. In a whole antibody molecule, the Fr region 
(amine group) of antibody usually present as the antigen binding sites in the common 
applications. Thus, other approach we designed is using BS3 to conjugate amine group of 
antibody with amine group of chitosan. EDC and NHS conjugation reaction requires a pH 
conditions at range of 4.5~7.2 to be efficient, which is correspond to the acidic condition 
during the dissolvation of the chitosan. On the other hand, the novel BS3 conjugation 
method needs an almost neutral condition to react; therefore, we prepared water soluble 
chitosan solutions for this case.   
Although chitosan Nps with a higher Ab ratio showed gradually enlarged particle size 
and reduced zeta potentials, this did not mean that there was a direct correlation between 
size and zeta potentials. Zeta potentials depend on the level of electrolyte pH, 
flocculation, instability, and temperature and so on. For example, the good dispersion 
stability is usually with high positive (or negative) level zeta potential at very low pH or 
high pH, the pH between 4 and 7.5 is the range has been indicated can initiate the 
instability of suspension. The higher the zeta potential either negatively or positively, the 
stronger the repulsion between colloids to overcome the van der waal attraction. 
Therefore, they are more electrically stabilized. In contrast, the colloids in suspension 
with low zeta potentials are susceptible to agglomerate or sediment so that they are easily 
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to form a larger particle size. In our case, a larger particle size was observed in the 
chitosan Nps with increased Ab portion as well as Ab linked chitosan Nps using BS3 
conjugation method. This is most likely due to the less stable condition of nanoparticles.  
The selection and volume of chitosan used during nanoparticle synthesis can lead to a 
large structural and functional versatility for this material. During the synthesis process 
with nucleic acids, many parameters were determent factors for the successful siRNAs 
delivery by chitosan Nps. For example, body distribution of nanoparticles after IV 
injection is highly influenced by their interaction with the biological environment, and 
this especially dependent on the physicochemical properties, such as the surface charge 
of the nanoparticle. The efficient delivery of siRNAs is also strongly depended on what 
kind of bio-environment they are delivered to and the size of the nanoparticles. These are 
closely related to the efficiency of cellular uptakes. Nanoparticles larger than 5nm in 
diameter do not readily cross the capillary endothelium. On the other hand, the enhanced 
vascular permeability in the liver, spleen, and some tumors permits the macromolecules 
and nanoparticles up to approximately 200nm in diameter to cross, it is known as the 
enhanced permeation and retention effect. The size of nanoparticles that is bigger than 
500nm was reported easier for the recognizetion of macrophages and completion of 
phagocytosis. The degree of polymerization of chitosan (DPn) as well as the fraction of 
N-acetylated units (FA) were reported to be important associated with gene silencing 
efficiency as well. For example, gene silencing is most efficient when chitosan with 
intermediate chain lengths, that is, DP(n) approximate between100 and 300 were used.  
[121]  
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The size, zeta potentials and stability of siRNA/Chitosan Nps are critical during siRNAs 
delivery and also depends on various parameters. Molecular weight of chitosan close 
related to the size of chitosan Nps,  the size is decreased as the molecular weight 
increased. 10kDa chitosan was proven to produce a 3500nm size of particles. A range 
between 65 to 170kDa chitosan can produce 200 to 300nm diameter of nanoparticles. 
[210] Our data are consistent with the results in these earlier studies. The nanoparticle 
size of approximately 270~290nms were observed by TEM and analyzed using zetasizer 
when chitosan with similar molecular weight were used. In contrast, zeta potentials will 
slightly increase as molecular weight increases at a range of 65kDa to 170kDa. [210] In 
the study of nanoparticle stability, lower molecular weight of 10kDa fail to complex and 
compact siRNA into stable particles and a higer molecular weight (>60kDa) is required 
to form a stable nanoparticles. [212]  
The DD value designated as the percentage of deacetylated primary amine groups along 
the molecular chain, which subsequently determines the positive charge density of the 
chitosan. Higher DD results in increased positive charge enabling a greater siRNA 
binding capacity. A relatively low DD value can decrease the charge of zeta potentials.  
In our cases, no retardation effect or unstability of siRNA conjugated chitosan Nps were 
observed during gel retardation study. It is because of the selected chitosan with MW 
between 65 to 170kDa and DD value of 75-85% were used.   
The N/P ratio between chitosan and siRNAs represented as the ratio of a mass per charge 
of chitosan 167.88( when 84% DD is used) to a mass per phosphate of 325Da siRNAs, 
this relationship can also be simply described as weight ratio.  They are also very 
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important component to modulate the size, zeta potential, and stability of nanoparticles.  
An w/w ratio of  37.5 ( approximately N/P ratio of 54 to 59) was considered in our study 
based on previous successful protein silencing. [210] They showed that this range of N/P 
ratio can balance the toxicity and stability of chitosan materials during siRNA delivery.  
Chitosan mediated siRNAs delivery is in a charge density-dependent manner and charge 
density strongly depends on the pH, or we can say a protonation level. The charge density 
of the delivery vehicle significantly impacts its interaction with components of the 
bloodstream and siRNA bindings. The comparative positive value of surface charge of 
the chitosan/siRNA complexes increased with increasing concentration of chitosan at a 
constant siRNA concentration. This net positive charge of the particles was desirable to 
prevent particle aggregation and promote electrostatic interaction with the overall 
negative charge of the cell membrane. It could probably explain why a higher Ab ratio, 
such as 30% Ab-Chi/siRNA Nps propably with less charge level, showed a less stable 
situation ( indicated by a lower level of zeta potential). In the study of macrophage 
uptake, some findings also indicated that highly charged particles can lead to complement 
activation of macrophages, whereas near-neutral particles show reduced phagocytic 
uptake.  
In summary, different parameters, such as molecular weight, DD value, N/P ratio, and pH 
level, are tightly related to the size, charge density, and stability of siRNA conjugated 
chitosan Nps. These characteristics of  the nanoparticles can further impact the 
transfection and gene silencing efficiency. We successufully synthesized differnt chitosan 
Nps with resonable size and zeta potentials value and minimized cytotoxicity based on 
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the earlier results established by many researchers. Especially, we developed and 
compared the properties of different ligands mediated chitosan Nps for macrophages 
subsets targeting. Additionally, we are first introduce a new Ab conjugation method with 
chitosan materials, in despite of the stability of Ab-WSC/siRNA Nps required further 





















PREVENTING CELL DEATH  
AFTER SPINAL CORD INJURY VIA TARGETED SIRNAS DELIVERY  
 
6.1    Introduction 
6.1.1    Macropahges Polarization and Their Role in Spinal Cord Injury 
Macrophages mediate a large scale of biological responses and play a key role in the 
immune systems. Modulation of macrophages to achieve an optimal host response could 
be crucial in the treatment of SCI. Recently, many groups reported the polarization of 
macrophages can influence neural behavior after SCI. Macrophages can perform 
distinctive functions by expressing either pro- or anti- inflammatory characteristics which 
depended on the stimuli received by the micro-environment. Classically or pro-
inflammatory-activated macrophages upregulate the level of pro-inflammatory cytokines 
and designated as M1 macrophages. On the other hand, alternatively activated M2 
macrophages, are associated with an anti-inflammatory profile and are crucial in tissue 
remodeling after inflammation, especially for axonal regeneration. [213] Granulocyte-
macrophage colony-stimlating factor (GM-CSF) and macrophage colony-stimlating 
factor (M-CSF) are commonly used for different phenotypic and functional changes in 
macrophage lineage populations. Generally, the polarization of M1 macrophages 
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can be activated by GM-CSF with combination of LPS and IFNγ,  and M2 macrophages 
can be primed by M-CSF with addition of interleukin-4 (IL-4) or IL-13 for M2a subset, 
combination of immune complexes and LPS for M2b subset, and  IL-10 or transforming 
growth factor-β (TGF-β) for M2c subset of M2 macrophages. [214] 
Many findings have been shown the phenomenon of macrophages polarization  and its 
presence after SCI, [213,215,216] with a long lasting expression of M1 macrophages at 
damadged spinal cord tissue. The  exacerbated secondary injury conditions after primary 
injury might due to this high level residence of pro-inflammatory macrophages. The 
hallmark of activated M1 macrophages is the upregulation of iNOS mRNA and its 
proteins expression at the earlier stage of SCI. [213]  
The detecting techniques of western blotting , polymerase chain reaction (PCR), and 
immunohistochemical analysis are commonly used to trace the expression of iNOS. 
Some studies reported that the iNOS mRNA occurred at 3-12 hours after SCI and 
gradually decreased afterwards using PCR analysis. Immunohistochemcial study shown 
the similar outcomes and suggested that iNOS positive cells peaked at 24 hours and 
declined to none expression within 3 days after injury. [217] The sum of earlier 
established study reveals that  the ideal determination and analysis time for iNOS 
expression is between 12 and 24 hours after SCI, which will applied to our study. 
Macrophages in the injured spinal cord origin from resident microglia and peripheral 
monocytes derived infiltrating macrophages.  M1 macrophages trafficked through 
adjacent arachnoid and pia mater of the spinal cord to the injured site while M2 
macrophages infiltrated through the brain-ventricular choroid plexus. [218] Compare to 
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the resident microglia, the infiltrated macrophages contributed to the phagocytosis, but 
not efficiently phagocytosing damaged and degenerated cells and debris in CNS as 
microglia in the early stage. However, they are the predominant cells associated with 
chemokins and many pro-inflammatory cytokines production, and has been identified to 
responding to the demyelination and axons degenerating, contributing to the secondary 
injury in spinal cord. [219] Therefore,  bone marrow-derived macrophages were selected 
for our in vitro studies due to the nature of these macrophages and their susceptibility to 
be polarized by stimuli.  
 
6.1.2    Route of Administration for SiRNAs Delivery  
Unfortunately, siRNAs associated delivery systems possessed some limitations during in 
vivo applications, such as insufficient biodistribution. Therefore, the route of siRNA 
administration is critical during the application and also responsible for  the dosage of 
siRNAs applied, the efficiency of tissue distribution, as well as the potential side effects. 
The different routes of administration of siRNA were investigated by many research 
groups to reveal the possible tissues that received siRNA corresponding to the 
administration. Intravenous administration route results in the accumulation of siRNAs in 
the kidney and pole/lumen of the proximal tubules, as well as urine due to the rapid 
excretion. Shawn D. et. al also detected the siRNAs uptake in the liver, pancreas, spleen 
and bone marrow using both hydrodynamic and standard IV. Intraperitoneal 
administration resulted in the siRNAs expression occurred in the spleen, liver and bone 
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marrow. Similar organs uptake, such as spleen, bone marrow as well as colon were also 
observed following rectal administration. [220] 
The drug delivery to CNS is more complicated than other organs due to the issue of 
blood-brain or spinal cord barriers. The optimal administration to bypass this issue is 
through direct intrathecal or intraventricular injection to CNS. To effectively detect the 
biodistribution of siRNAs, dye-labeled siRNAs were often used through directly 
visualizion of fluorescence signals in different tissues. Luo et. al has reported that 
fluorescence signal can be detected in the spinal cord and dorsal root ganglia after 
intrathecal delivery of siRNAs with transfection reagent. [221] The intrathecal injection 
can prevent certain degree of siRNA degradation which frequently occurred in the blood 
stream via serum protein.  Even though the CNS environment contain less nuclease 
compared to plasma and many other tissues, the assisted delivery strategies are still 
critical for successful siRNAs delivery to CNS because it not only can improve 
transfection efficiency, but also provide various functions by simply modification of the 
carriers. For example, conjugating the targeting motif to drug carriers and deliverying 
them to specific cell types or tissues for optimized siRNA uptakes in certain organs. 
[222]  
 
6.1.3    Nanoparticels Targeting Strategies to Macrophages via Fc Receptor 
Recently, many reports indicated that the limitation of onsites of siRNAs delivery could 
jeopardize its potential treatment. Therefore, our gear was directed to the development of 
targeting strategies in order to achieve more efficient protein silencing.  Since the 
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targeting strategies can be potentially applied to many disease-causing cells and tissues, a 
various functional add-ons, such as antibodies, aptamers, and peptides were widely used 
to guide its conjugated nanocomplexes to the desired cells or tissue sites. In addition, 
these ligands can be characterized with therapeutic, diagnostic, or barrier-avoiding 
properties to fulfill multivalent functionalities. Antibodies (Abs) have been commonly 
and successfully used as escort molecules for the targeted delivery of nanoparticles, and 
many are either proved by FDA or under development in clinical applications. This 
antibody mediated targeting approach is based on the assoication of the ligands with the 
receptors and receptor-mediated  endocytosis, which usually considered as active 
targeting.  In siRNAs studies, the targeted delivery provides the potential for efficient 
siRNA transfection into specific type of cells and avoiding nonspecific binding.    
Since mononuclear phagocyte was characterized of engulfing apoptotic cells, pathogens, 
and even microparticels via phagocytosis and destroy them, the passive targeting 
approaches can be used in the context of drug delivery to macrophages. It is close related 
to the intrinsic physicochemical properties of the carrier. Sometimes, nanoparticles can 
passively accumulate at inflamed sites because of the enhanced permeation and retention 
(EPR) effect. [223] However, in order for macrophages to uptake the desired therapetuics 
delivered by these nanoparticles, we can either use passive targeting approaches by 
modulating the physical properties of the nanoparticles or use a ligand associated active 
targeting strategies by selectively identify the surface marker of the macrophages. It has 
been postulated that both anionic and cationic charged particle and nanoparticle with size 
larger than 100nm are readily opsonized by the macrophages which is mainly resided in 
the liver and spleen. [223] Schafer et al. studied different particles uptake including 
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poly(methylmethacrylate), poly(alkylcyanoacrylate), and human serum albumin particle 
in human macrophages. The results indicated that nanoparticles made from the same 
material but of larger diameter were easiler for phagocytosis. [224] In phagocytes, 
endocytosis can be initiated by small particulate complexes formation, and phagocytosis 
can be initiated by a larger aggregates. Thus, the vital methodological tool to internalize 
the nanoparticles to specific macrophages is to use the active targeting via specific 
antibody-antigens reactions. 
Active targeting are commonly accomplished by modificating of the surface of 
nanoparticles via a targeting motif, a ligand with selective affinity, and can interact with 
specific receptors in certain cell types. Nanoparticles used for macrophage-targeted 
delivery can be associated with various receptors such as Fc receptors,  mannose, 
galactose, and sialic acid specific lectin-based receptors, lipoprotein receptors, and 
scavenger receptors. [223] The activation, recognition, endocytosis, secretion activities of 
the  macrophage depend on the surface receptors. Synthetic functionalized mannosyl 
ligands has been revealed to conjugate with various drug carriers: liposomes, chitosan, 
and gelatin nanoparticles in such way to increase the interaction with macrophages than 
unmodified nanoparticles. The macrophages uptake via Fc Receptors provide key role in 
active phagocytosis and endocytosis. Many studies reported that immunoglobulin and 
monoclonal antibody or its Fc fragment incorporated nanocomplexes present much 
higher binding and internalization by macrophages via Fc receptor-mediated endocytosis.  
Nano-delivery small molecules therapeutics were widely use for macrophage targeting in 
various pathologic conditions including mycobacterium tuberculosis, endotoxin-induced 
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lung inflammation , parasitic infection, as well as HIV/AIDS. Many of them are mediated 
through Fc receptors, and its associated drug delivery system is well developed. This 
mechanism of macrophage uptake is called antibody dependent cellular phagocytosis 
(ADCP). Briefly, IgG molecules that is specific for certain surface receptor of antigens 
can bind to these pathogens with their fragment antigen binding region (Fab region) 
which contains amine group, then their fragment crystallizable region (Fc regions) 
exposed to phagocytes in order to induce phagocytosis. The low affinity properties of Fc 
receptors can reduce the possible binding to antibody and agglutination when there is no 
present of antigen. [225,226]  
A detailed understanding of the functionality and property of these Fc receptors is critical 
during the application. Subfamilies of Fc receptors can be classified according to variable 
affinity and can also be classified based on the activating and inhibitory properties. It is 
very important to balance the expression between activating and inhibitory Fc receptors 
for normal immune responses.  There are some similarities of  FcγRs expression between 
human and mouse species, but do exist many differences which can complicate the 
clinical application. For example, mouse macrophages always express relative high levels 
of  FcγRI receptors at normal conditions, but the level of  FcγRI receptors expressed low, 
and high in inflamed human macrophages. The classification of similarity and difference 
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Although our study focused on murine macrophages, the terms associated for human Fc 
receptors are used in the here.   
Some experiment further indicated functionality of Fc receptors by blocking different 
classes of FcRs. The results showed a significant reduction of ADCP when block all three 
Fc Receptors with F(ab’)2 fragments.  Interestingly, the decreased ADCP was not 
observed when only blocking FcRI receptors (CD64), indicating that Fc receptor 
mediated phogocytosis only involved with Fc γRII and Fc γRIII (CD16 and CD32). [227] 
Furthermore, some results also indicated that blockage of either FcRII or FcRIII receptor 
didn’t remarkably influence the phagocytosis, but significant effected by the blockage of 
both receptors. This suggested that either of these two low-affinity Fc receptors is capable 
of functioning independently to initiate phagocytosis. [228] Therefore, the study of 
nanoparticle uptake by macrophages through phagocytosis can focus on either Fc γRII or 
Fc γRIII receptors, or both.  
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6.1.4    Targeting Macrophages in Spinal Cord 
The subsets of macrophages were revealed a markedly different biofunctional role in 
immune system as mentioned earlier, there is no doubt that discrimination between M1 
and M2 macrophages also strongly influence the targeting strategies to the macrophages. 
Many researchers focused on targeting tumor-associated macrophages for cancer 
treatment. These macrophages were favor the tumor growth via angiogenesis and 
metastasis, and they are usually consider as a M2-similar macrophages which particularly 
indicated by Arginase-1 and CD206-mannose receptor expression. However, the role of 
M2 macrophages in different bioenvironment could results in a completely opposite 
outcome.  In the case of spinal cord injury, the M2 macrophages can produce 
neurotrophic factors and promote the nerve outgrowth in either developing or mature 
neurons after SCI. [229] On the other hand, pro-inflammatory M1 macrophages can 
produce various cytokine such as TNF- α and NO and play an pivotal role in secondary 
injury. Therefore, the inhibitory molecules generated from M1 macrophages could be an 
important target in drug delivery to treat neural trauma and disease.  
The expression level of the receptors can be alternated depending on the changes in 
bioenvironment. The differentially higher expression of Fc receptors on the surface of 
macropahges was found in many rheumatoid arthritis studies, and also found in the case 
of SCI. Since inflammatory macrophages at rheumatoid arthritis joint over-expressed 
CD-64, CD64-directed immunotoxins has been reported to be useful for screening, 
diogonose or even treatment for rheumatoid arthritis. [230]  
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The surface markers after spinal cord injury were characterized as CD86, CD16/32 
positive M1 macrophages and CD206 positive M2 macrophages. [213]In the case of 
multiple sclerosis, surface marker CD40, CD86, CD64 and CD32 were overexpressed by 
activated microglia and macrophages throughout demyelination. [231] There is a 
significant increased M1 macrophages were observed at first day after SCI, however, the 
M2 macrophages featured with IL-4 receptor α chain and CD206-mannose receptor 
surface markers start upregulation from day 3 and significant increased at day 7. [218] 
This timeline is cohesive with the results demonstrated by Kristina Kigerl et al and 
Kyoung-Jin Min et al . [213,232]  The expression of CD16, CD32, and CD64 in different 
macrophage populations has also been indicated to correlated with phagocytic activity 
and phagocytosis efficacy.[233]( Also see 6.1.3) Therefore, Fc receptors mediated M1 
macrophage targeting can be a potential strategy in SCI study. 
 
6.2    Materials and Methods 
6.2.1    Cell Culture 
Bone marrow-derived macrophages (BMDM) from C57BL/6 mice were purchased from 
cell biologics LLD which purified by positive selecting CD11b using flow cytometry and 
were maintained in cell medium with Dulbecco’s modified Eagle medium/F12, 10 mM L-
glutamine, supplemented with 10% fetal bovine serum, 100 U/ml penicillin, and 100 
μg/ml streptomycin in the presence of GM-CSF (5ng/ml) or M-CSF(2500U/ml). The 
macrophage were seeded in 12- well or 24-well tissue culture plates and allowed to 
adhere for 24 hour at 37oC in humidified atmosphere containing 5% CO2.  
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6.2.2    Light Microscopic Studies on M1 and M2 Macrophages Morphology  
Macrophages incubated with GM-CSF were polarized to M1 macrophages by 
challenging with combination of LPS (Sigma) and IFNγ (B&D Research)  at higher 
concentration of 1μg/ml LPS+200 ng/ml IFNγ or at lower concentration of 100ng/ml 
LPS+20ng/ml IFNγ for 12 hours. Also, macrophages incubated with M-CSF were treated 
with IL-4 for 12 hours to activate M2 macrophages.  The control group is prepared by 
GM-CSF and without stimulation of any cytokines. The morphology of macrophages was 
imaged using Olympus IX 81 inverted microscope. 
 
6.2.3   In Vitro Experiment 
For siRNA experiment, the siRNA was mixed with desired volume of Lipofectamine 
2000 transfection reagent based on the instruction from the companies. Macrophages 
cultured in serum free medium were then incubated with 2μl of 20μm siRNAs per well 
for 48 hours (or 4 hours for comparision)  before challenged with medium containing 
100ng/ml LPS and 20ng/ml IFNγ for 12 hours. To screening most efficient iNOS 
siRNAs, macrophages were also received the same siRNA treatment but  stimulated with 
higher concentration of insults, that is, 1μg/ml LPS with 200ng/ml IFNγ. The target 
sequences of siRNA as listed here were used for screening.   
GAAACGUUAUCAUGAAGAU (siRNA1), CAUGGGAGCCACAGCAAUA 
(siRNA2), GGAGAUGGUCCGCAAGAGA (siRNA3) and 
GAUUUAGAGUCUUGGUGAA (siRNA 4).  In addition, three different 
siRNA/chitosan Nps were used as treatments during the experiment, which are 
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Chi/siRNA Nps, M-WSC/siRNA Nps, and Ab-Chi/siRNA Nps. Pre-prepared siRNA 
conjugated chitosan solution  at concentration of 2μl of 20μm siRNAs was added to each 
well containing serum free medium for 4 hours before low concentration of LPS/ IFNγ 
challenge. For all experiment, cells were incubated in fresh medium for 12 hours between 
treatment and challenge procedures.  In negative control groups, scrambled siRNAs (will 
not results in the specific degradation of iNOS mRNA) were synthesized with chitosan, 
instead of iNOS targeted siRNAs.   
 
6.2.4    Transfection Efficiency  
Bone-marrow derivate macrophages were cultured in a 12-wells dish at density of 1*106.  
Three different chitosan Nps were prepared as described 5.2.1section with exceptional of 
DY547 conjugated siRNAs (customized by GE Dharmacon, CO) were used with sense 
sequences DY547-CAUGGGAGCCACAGCAAUAUU and antisense 5’-
PUAUUGCUGUGGCUCCCAUGUU siRNAs with transfection reagents or siRNA 
conjugated chitosan Nps were incubated for 4 hours before imaging. The fluorescence 
signals and macrophage morphology was imaged by Olympus IX 81 inverted 
microscope. The overlapping of fluorescence and light microscopic images for each 
groups also performed to indicate the level of macrophage uptake.  
 
6.2.5    Western Blot Analysis of Gene Silencing 
The cells were treated and challenged as described in 6.2.3 section. Subsequently, each 
group of macrophages was incubated in ice-cold RIPA buffer (Pierce, Thermo Fisher 
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Scientific Inc, IL) containing 25mM Tris-HCl (pH 7.6), 150mM NaCl, 1% NP-40, 1% 
sodium deoxycholate, 0.1% SDS, and keep on ice for 5 mins. Macrophage lysate were 
gently collected using cell mini scraper and centrifuged for 15mins at 14000rpm at 4oC. 
Then supernatant were quantified  by BCA protein assay kit (Pierce), and equal amount 
of the proteins from different samples were loaded in 7.5% sodium dodecyl sulphate 
(SDS)-polyacrylamide gels and transferred to a PVDF membrane. Membrane were 
incubated in blocking buffer containing 1X Tris Buffered Saline with Tween® 20 
(TBST, Cell Signaling Technology, Inc.) and 5% w/v nonfat dry milk for 1 hour at room 
temperature. Immunoblotting was processed with incubating membrane with mouse 
specific primary antibody iNOS (#2982, Cell Signaling Technology, Inc.) and β-Actin 
Antibody (#4967, Cell Signaling Technology, Inc.) overnight at 4°C. Then, membrane 
was gentle agitated in blocking buffer containing anti-rabbit IgG, HRP-linked Antibody 
(#7074, Cell Signaling Technology, Inc.) for 1 hour at room temperature and developed 
in LumiGLO solution for 1 min at room temperature. The bands of interest were detected 
by Syngene GBox imager and the quantization of interest band was analyzed using Image 
J software. 
 
6.2.7    NO Assay 
The macrophages were  incubated with siRNA with or without transfection reagent for 48 
hours. Also, all four siRNA/chitosan Nps were also performed as treatment groups and 
incubated for 4 hours before LPS and IFNγ challenge. In two cases of Ab conjugated 
chitosan nanocomplexes, different level of Ab (10%, 20%, and 30%) incorporated with 
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chitosan were also analyzed.  Cells after received different treatments were then 
incubated in fresh medium for 12 hours before stimulated by 1μg/ml LPS and 200ng/ml 
IFNγ for 12 hours. Different samples were immediately collected and separately detect 
the values of nitrate (NO3-) and nitrite (NO2-) levels based on Nitric Oxide Assay Kit 
(Pierce). 
 
6.2.8    In Vivo Experiment 
All aspects of animal care and treatment were carried out according to the guidelines of 
Purdue Animal Care and Use Committee (PACUC). Female BALB/c mice with weight 
approximate 25g were used in this study. Spinal cord injury was induced similar to the 
surgical procedures described at 4.2.3 section with exception that  clip compression was 
used to spinal cord instead of forcep compression. The prepared chitosan solution 
described at 5.2.1section was centrifuged for 15 mins at 4 °C. The pellet was then diluted 
using RNase free water and prepared as 10μg siRNAs in 10μl chitosan Nps suspension. 
All siRNAs treatments were conducted by injecting 10μl solution to spinal cord via 
hamlton syringe with 30 Gauge needles for 10 mins.  
 
6.2.9    Western Blot Analysis for Spinal Cord Extracts. 
Mouse were deeply anesthetized, euthanized, and kept on ice at 24 hours after SCI. The 
injured spinal cord segments (0.5cm long) were rapidly removed and freeze in the dry 
ice. Before use, the frozen tissue were weighted and placed into vial with Triple-Pure, 
High Impact Zirconium Beads (1.5mm) and lysis buffer which containing RIPA buffer, 
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1x Halt Protease and phosphatase  Inhibitor Cocktail, and 1x EDTA (Pierce). The 
samples were then homogenized using BeadBug Microtube Homogenizer (Benchmark). 
The homogenate was centrifuged at 10,000 g for 5 mins at 4°C. The protein concentration 
of tissue lysates was then determined with a BCA Protein Assay Kit (Pierce). 50ul 
aliquots were subjected to 4–20% polyacrylamide gel, and the proteins were 
electrophoretically transferred to PVDF membrane filters. The membrane then were 
blocked with 5% nonfat milk in TBST for 1 hour at room temperature. After washing, the 
membrane were incubated with primary antibody solution containing iNOS, α-tubulin 
(1:1000, Cell signaling), Bcl-2 (1:200), and Bax (1:100) (Santa Cruz Biotechnology, Inc) 
separately overnight  at 4°C.  Next day, the membrane were washed for 3 times with 
TBST and probed with HRP conjugated secondary antibody for 1 hour at room 
temperature. Then, it is followed by the incubation of LumiGLO solution for 1 min at 
room temperature. The membrane was exposed to Syngene GBox imager and the density 
of the immunoreactive bands was quantified using ImageJ software. 
 
6.2.10    Statistical Analysis 
All data are shown with standard error of the mean ( + SEM).  The data was determined 
as normal distribution based on the level of skew and kurtosis less than 2 and 9. Tukey's 
HSC multiple comparisons tests were used.  Significance was determined by a P-value < 
0.05.   
 
 




6.3.1    Divergent Morphologies of M1 and M2 Macrophages  
In our results, we demonstrated that the activation of polarized macrophage is accompanied 
with the alternation in macrophage morphology. According to our results in Figure 6.1, the 
control group without any cytokine stimulation expressed a spindle-look or rounded shape 
of cells, and the induction of IL-4 results in a more long elongated shape of M2 
macrophages.  These extended shaped M2 macrophages also showed an enhanced 
adherence properties compared to M1 macrophages. Moreover, the stimulation of 
LPS+IFNγ results in more flattened round appearance as well as outspread cytoplasm in 
M1 macrophages.  In addition, a higher concentration of LPS+IFNγ is with similar but 












Figure 6.1  The macrophage morphology of inactivated macrophages (control), activated 
M2 macrophages, and activated M1 macrophages. Control group did not receive any 
cytokine activation. M2 macrophages were activated by IL-4 shown as M2(IL-4), and M1 
macrophages were stimulated by either high concentration of LPS+IFNγ or low 
concentration of LPS+IFNγ, indicating by M1 (LPS+IFNγ) (H) and M1 (LPS+IFNγ) (L) 
respectively.  
 
6.3.2    Efficient Transfection of SiRNAs Conjugated Chitosan Nanoparticles 
The intracellular distribution of siRNA with transfection reagent, Chi/siRNA Nps, M-
WSC/siRNA Nps, and Ab-Chi/siRNA Nps in the murine BMDM were imaged using 
fluorescence and light microscope. Customized DY547 dye conjugated with 5’end of 
siRNA sense strand were used to visualize the cellular uptake. In figure 6.2, DY547 signals 
were imaged using fluorescence microscope and expressed as the red fluorescence signals 
displayed in the first row.(Figure 6.2 A and B) It demonstrates the quantity and distribution 
of siRNAs or siRNA with chitosan complexes.  The second row (Figure 6.2 C and D) 
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showed images of macrophages, and the third row (Figure 6.2 E and F) showed an 
overlapping image of these two.  The results showed a comparison of the transfection 
efficiency between using transfection reagent (Figure 6.2 left column) and Ab conjugated 
chitosan Np mediated (Figure 6.2 right column) siRNA delivery. The endocytosis of Ab-
Chi/siRNA Nps was dramatically higher than using transfection reagent during a 4 hours 
incubation time. There is approximately 60~70% DY547-labled macrophages when using 
Ab-Chi/siRNA Nps delivery, comparing to 10~20% using transfection agent.  However, 
there is no significant difference between Ab-Chi/siRNA complexes with either M-
WSC/siRNA or Chi/siRNA complexes (Data not shown here).  
 




Figure 6.2  Illustration of transfection efficiency of siRNAs and siRNA conjugated Ab-
chitosan Nanoparticles. A and B are fluorescence images, indicating distribution of 
siRNA and siRNA loaded chitosan Nps.  C and D are macrophage images, and E and F 
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6.3.3    Protein Knockdown 
Following the confirmation of cellular uptake, the silencing effects of siRNA were 
performed using western blotting methods.  We used LPS+IFNγ to initiate the activation 
of M1 macrophages and used IL-4 to induce M2 macrophages.  The iNOS protein 
expressions were evaluated at the condition of activated M1macrophages, activated M2 
macropahges, and control group which is the macrophages without cytokine stimulation 
applied. There is no iNOS expressions were observed in either control group or IL-4 
activated M2 macrophages. In contrast, there was a significant increased level of iNOS 
expression found after M1 macrophages activation (Figure 6.3 A), especially under the 
simulation of a higher concentration of LPS+IFNγ (Figure 6.3 B). Four different siRNA 
sequences were applied seperately for 48 hrs before LPS+IFNγ  stimulation and were 
screened for an optimized silencing of iNOS expression. Combining low and high level 
of LPS+IFNγ stimulations, we conclude that the siRNA*2 showed a significant reduction 
of iNOS expression with p<0.001 and p< 0.01respectively.  Although the siRNA1 also 
shown a dramatically reduction of iNOS protein level, the results are more variable 
compare to the results of siRNA*2. Therefore, siRNA*2 were used in all following 
experiments for further studies.    
 
 




Figure 6.3  Screening of siRNAs for silencing of iNOS mRNA expression. Protein 
silencing efficiency of different sense and antisense strands of iNOS specific siRNAs. 
Control group represents the macrophages without any cytokine stimulation. IL-4 
represents M2 macrophages were activated by IL-4 cytokines for 12 hours. LPS+IFNγ 
(H) indicated the activated M1macrophages stimulated by 1μg/ml LPS +200ng/ml IFNγ, 
whereas LPS+IFNγ (L) indicated the activated M1macrophages stimulated by 100ng/ml 
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As we mentioned earlier, siRNAs can be transfected into macrophages using  transfection 
reagent, but have very limited transfection efficiency in a shorter incubation time.  Most 
commercially available transfection reagents require days of incubation time for 
optimized transfection.  In our study, we compared the iNOS reduction level between a 
48 hours incubation and a 4 hours incubation time. The data showed that a longer 
incubation time results in a dramatically downregulation of iNOS expression after low 
level of LPS+IFNγ stimulation to M1macrophages.  Moreover, there is a significant 
statistical difference of iNOS expression between without (Figure 6.4 LPS+IFNγ (L)) and 
with pre-treatments using 48 hours incubation of siRNAs, 10%Ab-Chi/siRNA Nps, M-
WSC/siRNA Nps, and Chi/siRNA Nps in activated M1 macrophages. 
(p<0.001;p<0.001;p<0.01;p<0.01 respectively shown in Figure. 6.4) It is noteworthy that 
there is no statistical differences were detected between siRNAs treatment for 48 hours 
and treatment for 4 hours, although the mean value for 4 hours incubation of siRNAs 
shows significant less reduction in protein silencing and showed no statistical difference 
compared to without treatment. The statistical differences were also observed between 
siRNAs treatment for 48 hours and scrambled siRNAs (N-siRNA)(p<0.001), and similar 
statistical outcomes were also observed when compare targeted siRNA* with scrambled 
siRNAs (N-siRNA) in different siRNA conjugated chitosan nanocomplexes including 
10% Ab-Chi/siRNA Nps, M-WSC/siRNA Nps, and untargeted Chi/siRNA Nps.   




Figure 6.4  Knockdown of iNOS protein activity. All groups were challenged with low 
concentration of LPS+IFNγ. SiRNA*2 (L) indicated using siRNA with transfection 
reagent treatment for 48 hours, and a 4 hours incubation treatment time was also 
performed. Different Ab combination ratio range from 10% to 30% in Ab-Chi/siRNA 
Nps was also tested for iNOS expression. The outcomes of mannosylated chitosan and 
untargeted chitosan mediated siRNA treatment were presented here as well. Last four 
group demonstrate the same transfection reagent and chitosan Np based siRNA treatment 
with exception of scrambled siRNA were applied.  Label siRNA* indicated the siRNAs 
used in all experiment was siRNA2 indicated in Figure 6.4.  Label N-siRNA indicated 
scrambled siRNA. * p<0.05; ** p< 0.01; *** p<0.001.  
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6.3.4    NO Reduction 
NO production, as a result of iNOS expression, is the direct detrimental molecules to 
exacerbate the primary SCI and to sabotage the neural functional recovery.  The level of 
NO production was evaluated in a pattern as that in western blotting studies. The LPS and 
IFNγ stimulation was applied to all groups except for control and IL-4 initiated M2 
macrophages. The results showed that all treatment groups with targeted siRNAs 
(siRNA*) showed a dramatically reduction of NO level. (p< 0.001 compare to without 
treatment in figure 6.5) It confirmed the silencing efficiency of siRNA*2 addressed in 
Figure 6.3. All the data are matching the results in protein expression study describe in 
6.3.3 with exception of the similar outcomes of NO reduction for three different siRNA 
conjugated chitosan complexes.  We also tested NO production after the treatment of 
siRNAs with transfection reagent and without transfection reagent. An increased NO 
level was observed when there is no transfection reagent applied, suggesting that the poor 
cellular membrane crossing of siRNA itself and failure of iNOS protein silencing. BS3 
crosslinker mediated Ab conjugated chitosan Nps with a low zeta potential and larger 
particle size were also tested. A slightly NO reduction indicate the this synthesis method 
needs a further improvement in order to successfully delivery siRNA and silencing the 
desired mRNA expression. (p<0.05) 
 




Figure 6.5  NO production of  macrophages without cytokine stimulation, activated M2 
macrophages stimulated by IL-4, and M1 macrophages challenged with LPS+IFNγ with 
and without siRNA related gene silencing treatment.  
 
Figure 6.6  NO production using scrambled siRNAs.  
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In contrast, we also performed all groups with scrambled siRNA (N-siRNA), and it fail to 
prevent the NO production and showed no statistical difference.(See Figure 6.6) 
The reduction ability of NO level using siRNA treatment with different sequences was 
screened before apply the experiments described at Figure 6.5. These results confirmed 
the knockdown ability of siRNA2 (siRNA*) as protein studies. The same NO assay also 
applied to evaluate the reduction level produced by two different Ab conjugated 
chitosan/siRNA Nps with various Ab ratio (from10%-30%).  There is no statistical 
difference of  NO level between different Ab ratio in each group. However, there is 
significant statistical difference between with and without chitosan/siRNA Nps treatment. 
(p<0.001) (Data not shown in here) 
 
6.3.5    Inhibition of Apoptosis Pathway after Spinal Cord Injury 
To exploit the functionality of targeted chitosan Nps in SCI conditions, we induced a 
compression injury to spinal cord of the mice to initiate the upregulation of  iNOS protein 
expression and NO production.  In our study, not only iNOS, but also Bax and Bcl-2 
protein expression were also investigated using western blotting methods at 24 hours 
after SCI. The upregulation of  iNOS expression was observed after SCI (See Figure 6.7). 
Pro-apoptosis Bax level were also appreciably increased, and anti-apoptosis Bcl-2 level, 
in the contrary, were significantly decreased after SCI, indicating the apoptosis signaling 
pathway was initiated or might be propagated after injury. Two treatment groups, Ab-
Chi/siRNA Nps and M-WSC/siRNA Nps, were performed to animal after SCI.  Both 
treatment groups showed a trend of elimination of iNOS and Bax expression and 
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relatively increased Bcl-2 levels, especially in the case treated with Ab-Chi/siRNA Nps. 
(*** p<0.001 for iNOS; ** p<0.01 for Bax and Bcl-2) These results suggest the 
neuroprotective role of siRNA conjugated chitosan Nps by preventing cell apoptosis 
signaling pathway after spinal cord trauma.  
      
Figure 6.7  Different proteins expression level after SCI with and without treatment of 
different chitosan nanoparticles carried siRNAs.  Ab-Chi/siRNA Nps were originally 
designed for M1 macrophages targeting, and M-WSC/siRNA Nps for M2 macrophages 
targeting. *** p<0.001 ** p<0.01; * p<0.05. 
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6.4    Discussion 
Many approaches were developed to modulate the function and secretion of macrophages 
to reduce the potential damage caused by secondary injury after SCI. The activation of 
M1 macrophages triggered by traumatic injury can initiate many pro-inflammation. Thus, 
preventing the proliferation of M1 macropahges or inibiting M1 associated pro-
inflammatory signaling pathways can suppress the inflammation initiated secondary 
injury. In our study, we targeted the hallmark expression of iNOS in M1 macrophages 
using siRNA gene silencing strategies and nanoscaled drug delivery systems. This work 
focused on targeting specific macrophages either to M1 or M2 macrophages using ligand 
conjugated chitosan/siRNAs Nps in SCI study. This is first time in nanoparticle targeting 
studies discriminating different subsets of macrophages. Since the overexpression of 
CD16/32 in M1 macrophages was observed at the insulted state of spinal cord, we also 
demonstrated the protential application of Fc receptor mediated M1 macrophages 
targeting. Most importantly, we indicate that this M1 macrophage targeting strategy can 
inhibited iNOS expression via delivery siRNAs and reduced cell damage and death after 
apply chitosan/siRNAs Nps by detecting apotosis cell singling protein marker Bax and 
Bcl-2 in vivo study.   
There are many studies has suggested the successful chitosan nanoparticle mediated 
siRNA delivery to macrophages, such as enhanced green fluorescent protein (EGFP) and 
TNF-α knock down in murine peritoneal macrophages. [189,196]  A rabies virus 
glycoprotein derived short peptide was designed as a AchR targeting ligand and it can 
assist the delivery of TNF- α siRNA to both macrophages and microglia cells for 
                                                                                                                                                                                                                                                              
155 
 
neuroinflammation and neuronal apoptosis reduction. [234] Different administration 
route of chitosan mediated nanoparticle has also been investigated for siRNA delivery to 
achieve potential gene silencing, for example through IP injection to macrophages, [196] 
and applied oral administration by  modificating chitosan to mannose-incorporated 
trimethyl chitosan-cysteine (MTC). [235] 
Due to the nature of chitosan polymers, there is no evidence of inflammatory reaction of 
material itself in the clinical study.  However, the purity, or we may say, the low degree 
of acetylation of chitosan could results in a unexpected inflammation. Several 
publications focused on the effects of chitosan materials towards macrophages culture. 
The outcomes are various. Oliveira MI et al. indicated that chitosan significantly down-
regulated expression of proinflammatory cytokines in macrophages, more interestingly, it 
also up-regulated anti-inflammatory cytokines and favors the M2 polarization. [236] 
These results were supported by the suppression of chitinous materials to nitric oxide 
production in the study of activated RAW 264.7 macrophages. [237] The mechanism of 
this suppression was further evaluated in other publications, and they suggested that there 
is a moderate activation of both iNOS and arginase in resident macropahges, but a strong 
expression of arginase with no altered NO production in inflammatory macrophages 
when treated with chitosan.  Since arginase induction is responsible for proliferation of 
many cell lines, it has the potentials to play a beneficial role in secondary injury 
treatment. [238] However, one paper reported that chitosan can induce apoptosis of 
macrophages through Fas signaling pathways. [239] 
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Since the iNOS is preferentially produced by classically activated proinflammatory M1 
macrophages, we focused on this subset of macrophages for targeting to attenuation the 
iNOS expression and its consequent NO prodcution. In addition, M1 macrophages 
upregulated the CD16/32, CD86, and MHCII expression after SCI. [213] Therefore, we 
can be able to differentiate this from anti-inflammation M2 macrophages which are 
designated by Arg1 and mannose receptor (CD206). The overexpression of receptors on 
M1 macropahges can be used as the potential target for siRNAs delivery. The increased 
iNOS expression starts few hours after SCI and dramatically reduced at day 3 after SCI, 
therefore, a time-corresponding cell surface marker expression, such as CD16/32 in M1 
macrophages can be considered as mediated receptors.  
Although it is known that macrophage internalization can be influenced by particle size 
and shape, as well as surface charge, it is still unclear about the mechanism of Nps uptake 
of macrophages. In general, it is believed that increased particle size (especially for 
nanoparticles size larger than 0.5um), higher zeta potentials, or long dimension of 
particles can be uptaken more rapidly by macrophages compare to smaller and neutral 
nanoparticles. Bone marrow and circulating blood derived monocytes and resident 
macrophages in every organs are usually represented as Mononuclear Phagocyte System. 
They are mainly responsible for pagocytosis. [240]  The broad spectrum of extracellular 
IgG molecules or IgG-coated partilces can bind and interact with Fc receptors 
(FcRII/CD16 and or FcRIII/32) expressed on macrophage and initiate phogocytosis or Fc 
receptor mediated endocytosis to enhance the activity of its uptake.   
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Recent findings indicate that FcγRIIA is expressed primarily in phagocytic cells and also 
present in natural killer (NK) cells. Inhibitory Fc Receptor FcγRIIB is constitutively 
expressed in T and B lymphocytes as well as phagocytic cells. Macrophages and some 
monocytes express FcγRIIIA, whereas FcγRIIIB is only expressed at neutrophils. 
[241,242] More studies further exploit and suggested that macrophages and monocyte-
derived dendritic cells and express high levels of activating FcγRs and moderated level of 
inhibitory ones for IgG. In comparison, conventional and plasmacytoid dendritic cells 
mainly express the inhibitory FcγR. [241] 
In our in vitro study, the pre-treatment approaches of siRNAs or its related drug delivery 
system were reported in majority of siRNAs gene silencing studies.  In this bone-marrow 
derived macrophages study, we apply either siRNAs or different chitosan/siRNA Nps to 
the cells before LPS+IFNγ initiated M1 macrophage activation. Our flow cytometery 
results addressed both expression of CD206 and CD16/32 before activation either M1or 
M2 macrophages. These results were fit with data reported by Flora Rey-Giraud et al. 
[243] The surface of the macrophages expressed both CD206 and CD16/32 receptors at 
inactivated state could lead to the successful cellular uptake of both mannosylated 
chitosan Nps and Ab conjugated chitosan Nps. A post-treatment was conducted during 
the study, however, cell viability is relatively reduced (data not shown here). Untargeted 
Chi/siRNA Nps also shown a significant reduction of iNOS, and it could due to the low 
molecular weight chitosan binds to the mannose receptors and promotes the nanoparticles 
internalization. [244]  
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We need to emphasize again that the expression of cells bearing surface receptors can be 
alternated, for example, accompanies with macrophage activation or spinal cord insults. 
The overexpression of CD16/32 after spinal cord injury can be beneficial to perform Fc 
receptor mediated phagocytosis and endocytosis as strategies using CD64-directed 
immunotoxins targeting to inflammatory macrophages at rheumatoid arthritis joint. [230]  
It is noteworthy that some studies also indicated that nanoparticle taken up via mannose 
receptor, Fcγ receptor, or through complement receptor pathways elicit an inflammation 
mediated immune response. It could due the phogocytosis process associated activation 
of certain signaling pathway.  It is not observed in our study based on the results in 
Figure 6.4 and 6.6, there is no trace of increased iNOS level and NO production for M-
WSC/N-siRNA Nps and Ab-Chi/N-siRNA Nps treatment (using scrambled siRNAs) 
compared to that without treatment after LPS + IFN γ challenge. However, other cytokine 
production did not included in our studies. Interestingly, Ab-Chi/N-siRNA Nps treatment 
showed visually but not statistically down regulation of iNOS expression. This 
phenomenon can not be explained until very recent report (Oct,2014) published at 
Santegoets K.C.M et al.  The studies showed that macrophages cultured with GM-CSF 
expressed a high level of inhibitory receptor, FcγRIIb, but a moderate level in the case of  
M-CSF cultured macrophages.  This inhibitory FcγRIIb plays a vital role in balancing the 
induced inflammatory responses to prevent excessive tissue damage. More importantly, 
they also demonstrated that the introduction of  soluble IgG immune complexes to GM-
CSF macrophages can inhibited cytokine production mediated by various Toll like 
receptors (such as 2,3,4, 7/8) via FcγRIIb signaling pathways. GM-CSF macrophages 
challenged with LPS (trigger TLR4 signaling) can initiated high level of cytokines such 
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as TNF-alpha. After co-stimulation with IgG immune complexes, dramatically reduced 
level of TNFα was observed in GM-CSF macrophages whereas a slightly increase level 
of IL-10 was occurred in M- CSF Macrophages. IgG immune complexes treatment alone 
did not initiated any detectable cytokines in GM-CSF but initiate low level of cytokine in 
the case of M-CSF macrophages. These results can be indicated due to the 
overexpression of  inhibitory FcγRIIb in GM-CSF, not in M-CSF. [245] The earlier study 
from this research group also showed immune complexes binding to FcγRIIb prevent the 
activation of  TLR4 signaling, this study could explain the slight, but not statistical 
significant, redcution in iNOS level, when Ab-Chi/siRNA Nps were applied in in vitro 
experiment.  
According to other earlier studies, the internalization by macrophages can be operated by 
all Fc receptors no mater they have activation or inhibition functions, but the endocytosis 
capacity and the route of oponized materials are different after internalization. One 
investigation suggests that internalization through activating FcγRs results in antigen 
degradation pathways and followed by the activation of T cells. On the other hand, 
Inhibitory FcγRIIB mediated macrophage internalization can transport undegraded 
antigen to B cells. [241] Also, it has been documented that large immune complexes or 
antibody-coated particles are susceptible to be uptaken via phagocytosis whereas the 
internalization of small immune complexes are through FcγR mediated endocytosis. This 
FcγR mediated endocytosis, compare to phagocytosis, require much different signal 
transduction mechanism which not involving Syk, SRTKs, and PI3K kinases initiated 
cytokine production.[246]    
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Moreover, our results indicated that an increased amount of Ab during nanoparticles 
synthesis did not result in more efficient gene silencing. 20% and 30% of Ab 
incorporated chitosan Nps has been shown an increased iNOS expression compare to the 
case using 10% Ab. The undesired concentration of antibody could affect phagocytosis. 
Some reports indicate that optimal phagocytosis occurred at antibody concentrations of 
10-100ng/ml. A higher risk of coagulation of nanoparticles could also jeopardize the 
reduction in iNOS expression because Nps with higher Ab ratios have a lower zeta 
potentials. Most possible reason is a high Ab ratio have a lower ratio of encapturing 
chitosan and limit synthesis of chitosan materials with desired amount of siRNAs.    
Chitosan mediated siRNA delivery system has demonstrate the improved transfection 
efficiency and gene silencing results, especially showed a shorter incubation time during 
the treatment when compared to using lipid-based transfection reagent. The complete 
depletion of iNOS expression is not set as our goal. But, in many situations, extremely 
efficient blocking of the specific protein expression is required. The efficiency of 
nanoparticle delivery usually can be effected by phagsome or phagolysosomal 
entrapment for phagocytic cell studies or by endosome for other cells. It could be a 
critical point in gene delivery to avoid degradation in the compartments of phagsome or 
endosome. Some groups reported that TNF- α specific siRNA conjugated large 
nanoparticles containing polyketal PK3 and chloroquine can significantly block targeted 
gene expression. It is due to the characteristics of  PK3 which not only protect the siRNA 
from serum nucleases, but most importantly, it can cause osmotic disruption of the 
phagosome. Therefore, the siRNA loaded nanocomplexes can be released to the 
cytoplasm. [247] Endosomolytc agent modified with maleic anhydride generating a pH- 
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sensitive maleamate bonds which can be cleaved under acidic endosome conditions in 
order to expose positive charged amine group and destabilized the endosome membrane 
for siRNAs to escape. [248,249]  In addition, other agents, such as an amphipathic 
poly(vinyl ether), were also well developed for this purpose of application. [250] 
Therefore, agents used in endosome escape can also be considered to prevent phagosome 
or phagolysosomal entrapment in the future studies to optimize silencing efficiency.    
The macrophage morphology studies showed apparent elongation or extension of M2 
macrophages, and it accompanied with no detectable iNOS expression and nearly same 
amount of NO production when compared to control group. It matches the 
neuroprotection properties of M2 macropahges reported in many earlier publications. 
Some researchers has also confirmed our results and elaborated the shape of macrophages 
correlated with the macrophages polarization and M2 macrophages are not associated 
with the initiation of imflammation, such as M1-polarizing stimuli triggered iNOS 
expression. [251]  
In conclusion, we introduce a siRNAs based gene silencing strategies to reduce the iNOS 
expression which usually triggered by activated pro-inflammatory macrophages after 
SCI. We successfully synthesized different ligand conjugated chitosan nanoparticles 
carring siRNAs. In vitro study, all siRNA loaded chitosan Nps showed significant iNOS 
knockdown with low cytotoxicity and efficient transfection. We further evaluate the 
targeting and gene silencing effects in animal studies. The results showed an alleviation 
of iNOS and Bax expression which is the indicator for pro-apoptosis cell death whereas 
an significant upregulation of anti-apoptosis marker Bcl-2 after Ab-Chi/siRNAs Nps 
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treatmen, indicating the effient targeting and therapeutic effects after attenuation of iNOS 




















There are many potential improvements that can still be provided to Ppy platform or 
chitosan nanoparticles mediated drug delivery system. Either polymer based drug carriers 
have been shown their unique functionality during the drug delivery.  
In this study, we focused on the structure, synthesis, and releasing profile for the Ppy 
platform to optimize localized drug release in spinal cord bio-environment. A further 
investigation on the 3D structure with increased drug loading capacitates would possibly 
be a next step. The figure 7.1 shows the Ppy nanotubes that we have manufactured with a 
larger surface area of polymers. It could enhance the drug release because  there is less 
possible drug entrapment due to larger areas exposure of materials. In figure 7.1, one PC-
12 cell was adhesived on the surface of Ppy matrix, indicating the small size of nanotube 
diameter.    
 




Figure 7.1  SEM image of single cell on Ppy nanotube structure. Scale bar = 5μm. 
Parameters of the EMF generator can also be modified, such as the frequency and the coil 
size.  We will start from a EMF stimulator with a low frequency instead of using current 
radiofrequency frequency. So we can further explore the cell responses to the low 
frequency stimulator (it has been well-established in the bio-electrical literatures) while 
detect the potential drug release. It could acheive a dual treatment through one 
application. Also, the penetration capacity of current induced by alternating 
electromagnetic field generator (described in 3.4 section) can also be further studied with  
a larger coil size and lower frequencies generator.  
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Figure 7.2  SEM images for cell adhesion on flat Ppy and Ppy Nws. Scale bar A=100μm; 
B=10μm; C and D=40μm. 
Moreover, from tissue engineering perspectives, this Ppy NWs platform can be 
potentially developed as biocompatible or even biodegradable substrates for cell adhesion 
and connection.  Collagen coated flat Ppy indicated the successful cell attachment see 
figure 7.2 A and there is apparent neurite extension. (see lower magnification figure 7.2 
B) However, there is no cell adhesion that was observed for the flat Ppy without collagen 
substrate coating (See figure 7.2C).  Interestingly, PC-12 cells successfully adhered to the 
PpyNWs structured platform without substrate assistance (Figure 7.2D).  A further and  
                                                                                                                                                                                                                                                              
166 
 
thoroughlly studies can be performed in the future as well.  Meanwhile, different drugs 
incorporation with this Ppy platform can also be discovered to improve neuronal recovery 
after SCI.        
For chitosan mediated siRNAs drug delivery system, co-polymerization and different 
targeting motifs can be exploited as an add-on to improve the existing nanoparticles, such 
as assisting nanoparticles cross spinal blood barriers. Thus, a simple IV injection instead 
of intrathecal injection can be used. Also, the study on M1 and M2 macrophages shifting 
through modulating various cytokines in bio-environment could lead to a new chapter of 
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